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Neuroinflammation in Alzheimer’s Disease: 
Characterization and Modification of the Response of Transgenic Mice 
to Intrahippocampal Lipopolysaccharide Administration 
 
Donna Lorraine Herber 
 
ABSTRACT 
Alzheimer’s disease (AD) is pathologically characterized by amyloid plaques, 
neurofibrillary tangles, inflammation, and neurodegeneration.   According to the amyloid 
hypothesis of AD, the central mediating event of the disease is the deposition of amyloid.  
The inflammation hypothesis of AD states that it is the inflammatory response to plaques 
and tangles, rather than the actual lesions, which causes the disease.  Studies described 
here combine the two approaches into a single model.  Four studies are presented using a 
basic protocol of intrahippocampal lipopolysaccharide (LPS) injection to stimulate 
inflammation in transgenic mice.  The first study looked at alpha7 nicotinic receptors 
during the glial response to Abeta deposits and LPS.  Reactive astrocytes which 
immunolabeled for alpha7 were co-localized with Congophilic deposits in APP and 
APP+PS1 mice, and increased after LPS injection.  Unfortunately, LPS injection into 
alpha7 knock out mice revealed the alpha7 labeling to be nonspecific.  The second study 
evaluated the time course of protein and gene expression after LPS injection into 
nontransgenic mice.  This experiment identified both a transient and chronic microglial 
inflammatory response, with changes in cell morphology.  The third study evaluated a 
similar time course in APP mice.  Concurrent with the inflammatory response, transient 
   vii 
reductions in Abeta burden were seen, though compact plaque load was unaffected.  The 
fourth and final study used dexamethasone to inhibit LPS-induced inflammation in APP 
mice.  LPS injection reduced Abeta burden, but was completely blocked by 
dexamethasone co-treatment.  Though dexamethasone inhibited LPS-induced CD45 and 
complement receptor 3 levels (markers of general microglial activation), dexamethasone 
had no effect on scavenger receptor A or Fc gamma receptor II/III levels.  An overall 
hypothesis regarding LPS mediated reductions in Abeta can be proposed:  It is not the 
presence of the LPS molecule, nor the upregulation of receptors involved in 
phagocytosis, but rather general glial cell activation that mediates Abeta removal.  Thus, 
a phagocytic cell must not only bind Abeta (by various receptors) but must also be 
capable of engulfing the material (via general cell activation).  Taken together, these 
studies suggest that some level of inflammation in AD is beneficial and responsible for 
maintaining a balance between amyloid deposition and removal. 
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Introduction 
In the United States, there are two approved therapeutic approaches to 
Alzheimer’s disease (AD) therapy.  The neurodegeneration seen in AD is mainly 
cholinergic, thus anticholinesterase drugs were developed to increase the half-life of 
acetylcholine in the synapse.  These drugs temporarily overcome cholinergic dysfunction, 
but have no effect on neurodegeneration.  Excitotoxicity has also been linked to the 
neurodegeneration of AD, thus n-methyl-d-aspartate (NMDA) receptor blockers have 
been developed.  These two courses of therapy are only modestly effective long term, and 
other targets have been identified.  At the center of new developments are various means 
of amyloid removal coupled with anti-inflammatory therapies.  Amyloid-depositing 
transgenic mice are useful in developing working models of AD as well as targeting new 
therapies.  Though amyloid deposition, inflammation, and cognitive impairment have 
been shown in various transgenics, there are limitations to the models, including a lack of 
neurofibrillary tangles, no apparent neuron loss, and minimal cholinergic deficits.  It is 
possible that enhancing the inflammatory state in the brain of these mice would more 
closely resemble the pathology of AD.  Lipopolysaccharide (LPS, endotoxin) stimulates 
the innate immune response, leading to gliosis in the central nervous system and has been 
used historically to induce inflammation.  The goals of the current studies are to evaluate 
and modify the response of transgenic mice to LPS administration. Inflammation would 
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potentially alter the glial response, amyloid load, cholinergic function, and neuronal 
survival of these mice. 
Alzheimer’s Disease 
Described by Alois Alzheimer almost a century ago, AD is pathologically 
distinguished by amyloid plaques, neurofibrillary tangles, and neuron loss (Alzheimer, 
1907).  The roles of neurofibrillary tangles and amyloid deposits in neurodegeneration 
and dementia of AD are controversial.  
Amyloid formation follows a series of steps beginning with the amyloid precursor 
protein (APP), a membrane associated protein (reviewed in Nunan & Small, 2002).  
Proteolytic cleavage of APP by secretases yields a variety of peptide products, some 
harmless, others neurotoxic.  Activity by gamma and beta secretases yields a 40 or 42 
amino acid product known as the amyloid β peptide (Aβ1-40 and Aβ1-42) that is released 
extracellularly.  The Aβ1-42  is the more insoluble form, which can form oligomers, fibrils, 
and ultimately diffuse and compact plaques.  The biochemical pathways associated with 
Aβ neurotoxicity are diverse, including direct interaction with neuronal cell surface 
proteins, and indirect actions of free radical production and glial activation (Canevari et 
al., 2004; Small et al., 2001; Walsh et al., 2002).  Compelling evidence supporting the 
key role of Aβ in the pathogenesis of AD are the genetic aberrations found in familial 
cases of the disease.  Mutations in APP and the presenilins (PS1 and PS2) have been 
identified in early onset AD, leading to the development of animal models.  Mice 
transgenic for human mutations of APP and PS1 have accelerated amyloid deposition and 
measurable cognitive deficits (Gordon et al., 2001).  In these mice, anti-Aβ antibody and 
nonsteroidal anti-inflammatory drug (NSAID) therapies led to reductions in Aβ and 
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behavioral improvements (Jantzen et al., 2001; Morgan et al., 2000; Wilcock et al., 2003, 
2004a,b).  Human trials using an active vaccination with Aβ1-42 are also showing 
promising results for halting the cognitive decline process, providing further evidence for 
the amyloid hypothesis of AD (Hock et al., 2003; Schenk, 2004).  
Neurofibrillary tangles are also abnormal deposits of insoluble fibrils which are 
formed in a similar aggregation cascade (Friedhoff et al., 2000).  Tangle accumulation 
inside neurons begins with tau, a microtubule associated protein.  Phosphorylation leads 
to dissociation of tau from the microtubules.  Hyperphosphorylated tau can polymerize, 
ultimately forming characteristic tangles which prevail even after the host neuron dies.  
Tauopathy is not exclusive to AD.  Frontotemporal dementias and Pick disease also 
exhibit tangles, as well as memory loss, personality changes, and extrapyramidal 
symptoms (Morishima-Kawashima & Ihara, 2002). 
Neuronal loss in AD is grossly seen in the overall atrophy of the cortical and 
limbic systems of the human brain.  Specifically, the basal forebrain cholinergic system is 
affected with overall loss of nicotinic and muscarinic receptors, as well as decreased 
acetylcholine release and choline acetyltransferase activity (Auld et al., 2002).  The exact 
mechanism of cell death is probably a combination of factors.  Accumulation of Aβ may 
lead to a localized autotoxic “innate immunoreaction” (McGeer & McGeer, 2002).  
Gliosis generates reactive oxygen species, cytokines, and chemokines, all potentially 
contributing to neurotoxicity (Akiyama et al., 2000).  Direct action of Aβ on neurons has 
also been hypothesized to cause excitotoxicity, followed by neuronal death (Canevari et 
al., 2004).  The preferential cholinergic loss in the disease may be attributable to the 
ability of Aβ to interact with alpha 7 nicotinic acetylcholine receptors (Bourin et al., 
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2003).  Current approved therapies for human use target cholinergic deficits with 
anticholinesterase action (Frisoni, 2001).  More recent therapies aim to prevent neuronal 
death via NMDA receptor blockade, preventing glutamate induced excitotoxicity 
(Reisberg et al., 2003).   
The role of inflammation in AD is complicated. At the center of the controversy is 
whether inflammation results from the pathology of AD or contributes to it.  Complex 
interactions between the complement cascade, cytokine and chemokine pathways, 
prostanoid mediated inflammation, and reactive oxygen species may all contribute to 
neurotoxicity (Akiyama et al., 2000). 
Cell mediators of the inflammatory process include the neurons themselves, 
microglia, and astrocytes.  Microglia, the resident macrophages of the brain (Kreutzberg, 
1996), and astrocytes are activated in AD brain compared to non-demented controls, and 
are associated with amyloid deposits (Lue et al., 1996; Vehmas et al.,  2003).  In vitro 
experiments have demonstrated the ability of microglia to produce cytokines (interleukins 
IL1β and IL6, tumor necrosis factor TNFα, transforming growth factor TGFβ) and 
reactive oxygen species when stimulated with Aβ (Colton et al., 2000; Lue et al., 2001; 
Small et al., 2001).  Immunohistochemical studies in human AD brain verify the presence 
of inflammatory cytokines associated with amyloid deposits (reviewed in McGeer & 
McGeer, 1995).   
Supporting the role of inflammation in AD related cognitive impairment are 
epidemiological studies indicating decreased risk of AD associated with chronic 
nonsteroidal anti-inflammatory (NSAID) therapy (Gasparini et al., 2004; In ‘t Veld et al., 
1998) .  Animal models concur, demonstrating decreased amyloid load after NSAID 
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treatment (Eriksen et al., 2003; Jantzen et al., 2002; Yan et al., 2003).  Human trials have 
been less promising, possibly due to the short duration (6-12 months) of such trials 
(Gasparini et al., 2004; McGeer et al., 1996; Szekely et al., 2004).     
Alpha 7 Nicotinic Acetylcholine Receptors in AD Pathology 
Cholinergic dysfunction is a hallmark of AD neurodegeneration.  Specifically, the 
basal forebrain cholinergic system is affected with overall loss of nicotinic receptors, as 
well as decreased acetylcholine release and choline acetyl transferase activity (Auld et al., 
2002).  The two main nicotinic acetylcholine receptors (nAChRs) in the human brain 
consist of α4β2 or α7 subunits, with smaller populations of α2-9 and β3-4 (Paterson & 
Nordberg, 2000).  α7 nAChRs are ligand gated ion channels consisting of five identical 
subunits, which conduct both sodium and calcium ions.  They are distinguishable from 
other nAChRs by affinity for α-bungarotoxin.  
In human AD brain, nicotinic receptor populations have been extensively studied.  
α7 nAChR levels are generally decreased in AD, though there are variations in reports 
(Perry et al., 2001).  Declines in receptors may be due to actual cell loss, or synaptic 
decline might account for the abnormalities.  Age related changes in α7 nAChRs 
expression in APP transgenic mice have also been reported (Dineley et al., 2001, 
2002a,b).  Focus has been on α7 nAChRs due to the potential interaction of the receptor 
with Aβ peptides.  Co-immunoprecipitation and receptor binding assays indicated Aβ1-42 
binds α7 nAChRs with high affinity, but not α4β2 nAChRs, in both human and rat tissue 
(Wang et al., 2000a,b).  Studies conducted with wild type α7 nAChRs indicate that Aβ1-42 
blocks the receptor (Grassi et al., 2003; Lee et al., 2003; Liu et al., 2001; Pettit et al., 
2001).  Glial cells may also be involved in the interactions of Aβ1-42 and α7 nAChRs as 
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recent reports have shown expression of these receptors by reactive astrocytes in human 
AD brain in association with amyloid deposits (Teaktong et al., 2003). 
Transgenic Mice 
The pathological markers of AD are amyloid plaques, neurofibrillary tangles, 
inflammation, and neuron loss.  Although genetic aberrations can account for only 5-15% 
of all AD cases, transgenic models have been developed that provide insight into the 
pathology.  Four genes are associated with amyloid deposition (reviewed in Morishima-
Kawashima & Ihara, 2002).  Early onset familial AD has been associated with genes 
coding for APP, PS1, and PS2 (Goate et al.,1991; Levy-Lahad et al., 1995; Sherrington et 
al., 1995).  Many APP mutations have been described, resulting in preferential cleavage 
by beta and gamma secretases, or by increasing formation of Aβ1-42, the more insoluble 
form of Aβ.  The presenilins have been identified as components of the gamma secretase 
complex (De Strooper, 2003).  In contrast, mutations in PS1 or PS2 lead to enhanced 
activity of gamma secretase, thus increasing production of Aβ.  A susceptibility to AD 
has been associated with the apolipoprotein E4 allele, leading to increased amyloid 
deposition through an unknown mechanism (Corder et al., 1993).  Mutations coding for 
tau have been identified in frontal temporal dementia and Parkinson’s disease, but not in 
AD.  In humans these mutations result in the hyperphosphorylated state of tau, 
neurofibrillary tangles, and neuronal loss.   
Transgenic mouse models of AD are limited in their pathology, but are useful for 
studying amyloid deposition.  Mutated forms of human APP when expressed in 
transgenic mice leads to an age related deposition of amyloid and inflammatory gliosis.  
Mice transgenic for PS1 mutations do not show significant pathology.  However, double 
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cross of the APP mouse line with PS1 yields accelerated amyloid deposition, 
inflammatory markers, down regulation of genes associated with learning and memory, 
and cognitive deficits, without neurotoxicity (Dickey et al., 2003; Duff et al., 1996; 
Gordon et al., 2001, 2002; Holcomb et al., 1998).  The discrepancy between these 
transgenics and human AD brain lies obviously in the lack of neuron loss and tangles.   
The specific role of the cholinergic system in AD may be explored using nicotinic 
receptor knockout mice.  As previously discussed, the ability of Aβ to interact with α7 
nAChRs makes this ion channel of particular interest.  Mice transgenic for a homozygous 
null mutation of the α7 nAChR gene are viable and fertile, without any apparent gross or 
cellular nervous system disturbances, neurological or behavioral dysfunction (Orr-
Urtreger et al., 1997; Paylor et al., 1998).  A role for α7 nAChRs in learning and memory 
has been presumed, thus the lack of a behavioral phenotype in these mice may be due to 
compensation by other populations.  In vivo examination of α7 nAChRs during 
inflammation- and Aβ- induced gliosis and neurotoxicity might be accomplished with 
these mice. 
Lipopolysaccharide as a Neuroinflammatory Agent 
Lipopolysaccharide (LPS) is a Gram-negative bacterial cell surface proteoglycan, 
also known as bacterial endotoxin, which triggers an inflammatory response by the host 
(Palsson-McDermott & O’Neil, 2004).  LPS binds to circulating LPS binding protein, 
which subsequently transfers the LPS to soluble or cell membrane bound cluster 
differentiation marker CD14, a common receptor for bacterial components (Heumann & 
Roger, 2002).  The CD14 protein does not contain an intracellular domain, so interaction 
with additional components is likely.  Toll like receptor 4 (TLR4), as well as myeloid 
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differentiation protein MD2, form a complex through which LPS:CD14 can transduce a 
signal (Thomas et al., 2002).  Multiple cascades are involved in the signal transduction, 
with nuclear factor NFκB as a key player (Sen & Baltimore, 1986).  Downstream gene 
activation leads to the production of cytokines, reactive oxygen species, and prostanoids 
stimulating the cellular inflammatory response. 
Historically, LPS has been used to mimic the inflammatory conditions seen in 
neurodegenerative diseases.  Acute and chronic application of LPS into the brain 
ventricles of rats resulted in gliosis, cytokine production, cognitive deficits and 
neurotoxicity (Hauss-Wegrzyniak et al., 1998a,b, 2000, 2002; Willard et al., 1999).  
Pharmacological intervention with steroids, NSAIDs, antioxidants, or NMDA receptor 
antagonists attenuated some of the effects of LPS (Castano et al., 2002; Hauss-
Wegrzyniak et al., 1999a,b; Jain et al., 2002; Kheir-Eldin et al., 2001; Szczepanik et al., 
2003; Wenk et al., 2000, 2002; Willard et al., 2000).   
With the introduction of amyloid depositing transgenics, LPS has been 
administered to accelerate Aβ deposition, activate glia, and trigger neurotoxicity (the 
latter a key component of AD that is lacking in these models).  The experimental 
conditions of reports vary including the type and age of transgenic animals used; type, 
dose and route of administration of LPS; and post injection survival time.  In some cases 
amyloid deposition was triggered (Qaio et al., 2001; Sheng et al., 2003; Sly et al., 2001), 
while in others amyloid clearance resulted (DiCarlo et al., 2001; Quinn et al., 2003).  
When considering the species of Aβ1-40 and Aβ1-42, the main indicator of Aβ reduction 
seems to be closely related to plaque load and survival time.  Aged animals with 
significant amyloid deposits, surviving several days post injection, showed clearance of 
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Aβ deposits after LPS treatment.  Compact plaques detected by either Congo red or 
thioflavin-S staining were inconclusively affected. In vitro studies show that microglia 
and as well as astrocytes react to LPS with phagocytic activity, as well as prostaglandin, 
cytokine, and nitric oxide production (Kalmar et al., 2001).   
The ability of LPS to cause neuron death appears to be duration and region 
specific.  Chronic infusion of LPS into the brain ventricles of rats resulted in neuron loss 
limited to the forebrain cholinergic nuclei (Hauss-Wegrzyniak et al., 1998a, 1998b, 2000, 
2002; Willard et al., 1999).  However, acute LPS injection into the brain parenchyma 
such as the anterior cortex and hippocampus did not triggered cell death (Kim et al., 
2000; Herber et al., 2004a,b).  An exception is the dopaminergic system which does show 
susceptibility to the degenerative effects of LPS (Kim et al., 2000; Castano et al., 2002).   
Taken together, stimulating an inflammatory response in the brain of transgenic 
mice should lead to a better understanding of the pathogenesis of AD.  Studies described 
herein address the effects of inflammation on gliosis and amyloid burden in these mice.
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Chapter 1 
 
Biochemical and Histochemical Evidence of 
 
Nonspecific Binding of α7 nAChR Antibodies to Mouse Brain Tissue 
 
Abstract 
 
Alpha 7 nicotinic acetylcholine receptors (α7 nAChRs) are involved in learning 
and memory, and are implicated in the pathology of Alzheimer’s disease and 
schizophrenia.  Detection of α7 subunits can be accomplished via immunodetection or α-
bungarotoxin binding techniques.  In studies described here, standard protocols for 
immunohistochemistry and Western blotting were followed using several commercially 
available antibodies.  Various mice were evaluated including nontransgenics, APP, PS1, 
APP+PS1, and α7 knockouts.  Initial results with amyloid depositing mice revealed α7 
immunolabeled astrocytes, in addition to expected neuronal staining.  Subsequent studies 
with intrahippocampal injections of lipopolysaccharide into α7 knockout mice showed 
that both neuronal and astrocytic labeling by α7 antibodies was nonspecific.  On Western 
blots of mouse brain proteins, none of the bands detected with antibodies directed against 
α7 subunits diminished in the α7 knockout mice.  Although LPS related changes in the 
expression of some bands was found, these also were unaffected by the α7 genotype of 
the mice.  In general, the Western staining patterns for these antibodies revealed few 
overlapping bands.  These immunodetection data are in contrast to genotyping results and 
mRNA analyses which confirmed the disruption of the α7 allele, and lack of α7 message 
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in the knockouts.  These findings suggest caution in interpreting results using several 
commercially available α7 nicotinic receptor antibodies.   
Introduction 
Cholinergic dysfunction is a hallmark of Alzheimer’s disease (AD) 
neurodegeneration.  Specifically, the basal forebrain cholinergic system is affected with 
overall loss of nicotinic receptors, as well as decreased acetylcholine release and choline 
acetyltransferase activity (Auld et al., 2002).  In vertebrates, the two main nicotinic 
acetylcholine receptors (nAChRs) in the brain are α4β2 and α7, with smaller populations 
of α2-10 and β3-4.  α7 is a ligand-gated ion channel consisting of five identical subunits, 
with a high relative calcium permeability, and distinguishable from other central nervous 
system nAChRs by its affinity for α-bungarotoxin (McGehee & Role, 1995; Seguela et 
al., 1993).   
In human AD brain, nicotinic receptor populations have been extensively studied.  
α7 levels are generally decreased in AD, though there are variations in reports (reviewed 
in Perry et al., 2001).  Declines in receptors may be due to cell loss or synaptic decline.  
Age-related changes in α7 expression in mice transgenic for a human mutated Alzheimer 
precursor protein (APP) have also been reported (Dineley et al., 2001; 2002a,b).  
Particular focus has been on α7 due to the potential interaction of the receptor with Aβ 
peptides.  Co-immunoprecipitation and receptor binding assays indicated Aβ1-42 binds α7 
with high affinity, but not α4β2, in both human and rat tissue (Wang et al., 2000).  
Studies conducted with wild type α7 receptors indicate that Aβ1-42 blocks the receptor 
(Grassi et al., 2003; Lee et al., 2003; Liu et al., 2001; Pettit et al., 2001).  Glial cells may 
also be involved in these interactions as recent reports have shown expression of α7 by 
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reactive astrocytes in human AD brain, particularly in association with amyloid deposits 
(Graham et al., 2002; Wevers et al., 1999; Teaktong et al., 2003).   
In these experiments, we used standard protocols for immunostaining and 
Western blot analysis of α7 nAChR subunits in murine models of Alzheimer’s disease 
and neuroinflammation.  Several commercially available antibodies were evaluated, and 
the results compared to genotyping and RNA analyses.  Initially, four genotypes resulting 
from breeding transgenic mice carrying either mutant APP or presenilin 1 (PS1) 
transgenics were examined for α7 expression.  Various reports in the literature led us to 
expect decreases in levels of nicotinic receptors in amyloid-depositing mice, such as the 
APP and APP+PS1 transgenics.  Though no decreases in neuronal staining was seen, a 
surprising finding was α7-immunopositive astroglia in apposition with compact plaques 
in APP and APP+PS1 mice, but not PS1 or nontransgenics.  In order to determine if 
amyloid was causing the astrocytic α7 expression, or if it was part of a more general 
inflammatory response, we injected LPS intrahippocampally into APP and nontransgenic 
mice.  Immunohistochemical analysis revealed many α7 positive astrocytes in the 
injected animals, leading us to believe the expression was part of a general inflammatory 
response.  In a final experiment using α7 null mice, the specificity of the antibodies was 
tested under both control and LPS stimulated conditions.  No discernible differences were 
seen between α7+/+ versus α7-/- mice with any antibody used, regardless of procedure.  
Genotyping and RNA analyses confirmed the disruption of the α7 allele and lack of α7 
message in the knockouts.  We therefore conclude that commercially available antibodies 
against α7 as used in the methods detailed here fail to specifically detect the subunits.   
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Materials and Methods 
Mouse Strains 
Transgenic mice carrying an APP (Tg2576) and/or PS1 mutation were bred as 
described previously (Holcomb et al., 1998).  Nontransgenic littermates were used as 
controls.  Alpha-7-null mutant mice, originally described by Orr-Urtreger and colleagues 
in 1997, were derived from heterozygous breedings of animals purchased from Jackson 
Laboratories (Bar Harbor, ME).  Nontransgenic and homozygous null mice from this 
cross were used in this study.  Animals were group-housed under a 12 hr light-dark cycle 
with free access to chow and water.  Experimental groups were balanced regarding age 
and gender. 
Genotyping 
APP and PS1 lines were analyzed as previously reported (Gordon et al., 2001).  
Mice from the α7 null mutation line were genotyped as follows: 2 mm diameter ear clips 
from the α7 heterozygous breedings were digested and the DNA extracted using Qiagen’s 
DNeasy® Kit (Valencia, CA), per the manufacturer’s instructions.  Jackson Laboratories 
supplied the sequence of primers used to identify either the neo-cassette of the null 
mutation or the wild type allele, for use with the polymerase chain reaction (PCR): 
Forward 5'CCTGGTCCTGCTGTGTTAAACTGCTTC3'; Reverse-WT (α7+) 
5'CTGCTGGGAAATCCTAGGCACACTTGAG3'; Reverse-Neo (α7-) 
5'GACAAGACCGGCTTCCATCC3'.  Thermocycling conditions were as follows: 95°C 
for 4 minutes; 30 cycles of 95°C for 15 seconds, 60°C for 60 seconds, 72°C for  
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60 seconds; 72°C for 7.5 minutes; store at 4°C.  PCR products were run on a 1% agarose 
gel, using ethidium bromide ultraviolet (UV) detection of bands at 440 bp (α7+) or  
750 bp (α7-). 
Intrahippocampal Injections 
APP mice aged 16 months, α7 null mice aged 11 months, and their nontransgenic 
littermates were used in these studies.  Mice were anesthetized using isoflurane and 
immobilized in a stereotaxic apparatus.  One microliter injections of either saline or  
4 µg/µl lipopolysaccharide (Salmonella abortus equi, Sigma, Saint Louis, MO) were 
delivered over a two minute period into the hippocampus (stereotaxic coordinates from 
bregma: -2.7 mm posterior; +/-2.5 mm lateral; -3.0 mm ventral).  This procedure had 
been previously demonstrated in our lab to induce a neuroinflammatory response without 
adversely affecting animal survival (DiCarlo et al., 2001).  All animal work was 
conducted under National Institute of Health guidelines, and approved by the University 
of South Florida’s institutional animal care and use committee.   Animals were singly 
housed for the 7 day post treatment survival period under standard vivarium conditions. 
Tissue Preparation 
Mice were anesthetized with pentobarbital (200 mg/kg, ip), then perfused 
transcardially with 25 ml of saline.  The right hemisphere of the brain was dissected into 
regions and stored at –80°C for subsequent biochemical analyses.  For 
immunohistochemistry, left hemispheres were transferred into a 4% paraformaldehyde 
solution for 24 hr, then processed through a cryprotection schedule of 10, 20, then 30% 
sucrose (24 hr in each solution).  The tissue was sectioned horizontally on a sliding 
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microtome at 25 µm.  Sections were then stored in Dulbecco’s phosphate buffered saline 
pH 7.4 (DPBS) with sodium azide (100 mM) at 4°C. 
RNA Analysis 
Mice obtained from the α7 heterozygous breedings were analyzed for mRNA 
using reverse transcription followed by PCR.  The procedure was originally described in 
detail elsewhere (Dickey et al., 2003).  RNA was extracted from the injected 
hippocampus of α7+ and α7- mice, using Qiagen’s Rneasy® procedure (Valencia, CA).  
RNA concentration was determined with Molecular Probes RiboGreen® RNA 
quantitation kit (Molecular Probes, Eugene, OR).  Reverse transcription with mMLV 
(Invitrogen, Carlsbad, CA) was performed, and the resulting cDNA subjected to PCR 
using Amplitaq Gold (Applied Biosystems, Foster City, CA).  Primers used to identify α7 
were directed towards portions of exons 9-10: F5’GTGGGCCTCTCAGTGGTCGT3’; 
R5’GTCCCCATCAGAGGGGTGTG3’.  Thermocycling conditions were as follows: 
95°C for 3 minutes; 45 cycles of 95°C for 15 seconds, 60°C for 60 seconds, 72°C for 60 
seconds; 72°C for 7.5 minutes; store at 4°C.  PCR products were run on a 1% agarose 
gel, using ethidium bromide UV detection of bands at 381 bp. 
Histology 
Immunohistochemical analysis of α7 nAChRs was performed using 25 µm free 
floating sections spaced 300 µm apart through the hippocampus.  Details of this 
procedure were originally described elsewhere (Gordon et al., 1997).  All steps were 
performed on a rotating platform at approximately 40 rpm, room temperature, unless 
otherwise stated.  Sections were blocked for endogenous peroxidases (10% methanol,  
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3% hydrogen peroxide in DPBS) for 15 minutes, then washed 3 x 5 minutes with DPBS.  
The tissue was then permeabilized in a solution of 100 mM lysine, 0.2% triton x-100, and 
4% normal goat or horse serum (Pel Freeze, Rogers, AK) in DPBS for 30 minutes.  
Sections were then incubated overnight in the appropriate primary antibody in DPBS and 
4% serum, without shaking (Table 1).  The following day, sections were incubated with 
shaking in primary antibody for one hour.  Sections were then washed 3 x 5 minutes with 
DPBS, and then incubated in appropriate biotinylated secondary antibody (Vector 
Laboratories, Burlingame, CA) at a concentration of 0.5 µg/ml in DPBS and 4% serum, 
for two hours.  Sections were washed 3 x 5 minutes with DPBS, and then incubated for 
one hour in Vectastain® Elite® ABC solution (Vector Laboratories, Burlingame, CA), 
using 8 drops each of components A and B per 100 ml of DPBS.  Sections were then 
washed 2 x 5 minutes with DPBS, followed by a single wash in tris buffered saline, pH 
7.6  (TBS) for 5 minutes.  The tissue was then incubated with a solution of 0.5% 
nickelous ammonium sulfate hexahydrate and 0.05% diaminobenzidine in TBS for 5 
minutes.  Color development was achieved by the addition of 0.03% hydrogen peroxide, 
and incubation for an additional 5 minutes, followed by three final washes.  Controls for 
nonspecific binding of the secondary antibody were performed by excluding primary 
antibodies.  Stained sections were mounted onto slides and air dried overnight.  Slides 
were then processed through a dehydration schedule of 10 dips in water, followed by 2 x 
3 minutes in each of 25%, 50%, and 75% ethanol, then 3 x 5 minutes in each of 95% 
ethanol, 100% ethanol, and Histo-Clear (National Diagnostics, Atlanta, GA).  Slides were 
cover slipped with DPX (E.M. Sciences, Fort Washington, PA) and allowed to dry 
overnight.   
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In some cases, tissue stained with α7 antibodies was counterstained with Congo 
red to verify location of compact plaque deposits.  For this counterstain, immunostained 
sections were slide mounted and allowed to dry overnight.  The slides were then hydrated 
for 30 seconds in water.  Slides were then submerged for 20 minutes in a solution of 80% 
ethanol supersaturated with sodium chloride, then made alkaline with a final 
concentration of 0.01% sodium hydroxide.  Slides were then incubated for 30 minutes in 
a separate portion of alkaline alcoholic saturated sodium chloride containing 0.2% Congo 
red dye (solution filtered prior to use).  Slides were then dehydrated with 8 dips in 95% 
ethanol, then 8 dips in two baths of 100% alcohol.  The tissue was finally run through 3 x 
5 minutes of xylene and cover slipped with DPX. 
Western Blotting 
Mice obtained from the α7 heterozygous breedings were analyzed for protein 
using SDS-PAGE followed by Western blot.  Cerebral cortex previously stored at –80°C 
was homogenized in 10 mM HEPES buffer pH 7.4 containing a protease inhibitor 
cocktail (Roche, Indianapolis, IN).  Crude protein concentrations were determined by the 
Bradford method using Bio-Rad Protein Assay Dye Reagent (Hercules, CA).  Samples 
were denatured with Bio-Rad Laemmli sample buffer by boiling for 5 minutes. 10 µg of 
protein was loaded per well, and proteins separated using 10% polyacrylamide Bio-Rad 
Ready Gels.  Bio-Rad Precision-Plus Protein™ All Blue molecular weight standards were 
run for band identification.  The separated proteins were transferred to Immobilon™-P 
polyvinylidine fluoride membranes and immunoblotted (Millipore, Bedford, MA).  
Membranes were first blocked with 5% nonfat dry milk in borate-buffered saline pH 8.5 
and 0.05% Tween-20 (BST) for one hour on a rocking platform at room temperature.  
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Membranes were then incubated with primary antibody in 2.5% nonfat dry milk in BST 
for one hour (Table 1).  After washing 3 x 5 minutes with BST, blots were incubated with 
appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) at a 1:10000 dilution in 2.5% milk-BST for 30 minutes.  
Finally, membranes were triple washed in BST.  Bands were identified using Western 
Blotting Luminol Reagent (Santa Cruz Biotechnology, Santa Cruz, CA) for 
chemiluminescent detection and subsequent film exposure for 0.5-5 minutes.  The 
presence of α7 protein was verified by comparing the protein bands to the molecular 
weight standard markers.  The expected molecular weight of the α7 subunit was 56 kDa. 
 
Table 1.  Primary Antibodies Used for Immunodetection 
 
Clone Type Source Immunohistochemistry 
Titer 
Western Blot 
Titer 
     
319 Rat 
monoclonal 
 
Sigma 1:5000  1:1000 
306  Mouse 
monoclonal 
 
Covance 1:3000  1:50 
H-302 Rabbit 
polyclonal 
 
Santa Cruz 1:200 1:100 
 
 
Results 
Standard protocols for immunohistochemical and Western blot detection of α7 
nAChR subunits were followed using several commercially available antibodies.  These 
results were ultimately compared to genotyping and mRNA analyses of the α7 subunit.  
Initially, four genotypes resulting from breeding of APP and PS1 transgenics were 
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examined for α7 expression.  Previous data had been published demonstrating the 
amyloid burden, gliosis, and behavioral phenotype of these mice (Gordon et al., 2001, 
2002).  The antibodies used for the current study included a rat monoclonal antibody 
(mAb 319), a mouse monoclonal (mAb 306) and a rabbit polyclonal (pAb H-302).  In 
nontransgenic mice (Fig. 1), distinct ubiquitous positive immunostaining was seen 
throughout the brain with mAb 319.  Regions analyzed included the dentate gyrus of the 
hippocampus, frontal cortex, striatum, and cerebellum.  These results are consistent with 
previous reports (Dominguez del Toro et al., 1994).   
 
Figure 1.  Immunolabeling by α7 antibodies in nontransgenic mouse brain.  Horizontal 
sections were immunostained using mAb 319 at a 1:5000 dilution.  Ubiquitous neuronal 
stain was seen in all regions examined including the dentate gyrus of the hippocampus 
(A), cerebral cortex (B), striatum (C), and cerebellum (D).  Scale bar = 100 µm. 
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Figure 1.  Immunolabeling by α7 antibodies in nontransgenic mouse brain. 
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Mice transgenic for APP+PS1 were next analyzed.  Distinct neuronal staining was 
noted with mAb 319 (not shown), similar to that seen in nontransgenics.  A comparison 
of nontransgenic versus APP+PS1 mice revealed no differences in the intensity of 
neuronal staining in any region.   In amyloid bearing regions such as the hippocampus 
and cortex, immunolabeling of reactive astrocytes was also noted.  The cells were 
deemed astrocytes based on their size, morphology, and distribution within the laminated 
regions of the hippocampus.  The α7 immunopositive astrocytes seemed to cluster around 
amyloid deposits, which was confirmed when brain sections were counter stained with 
Congo red (Fig. 2).  This micrograph shows mAb 319 positive cells associated with a 
Congophilic plaque.  APP mice showed similar patterns of astrocytic staining, but to a 
lesser degree, possibly due to the lower amyloid burden in these mice (data not shown).  
PS1 mice resembled nontransgenics; rarely were α7 immunolabeled astrocytes seen in 
those mice.   
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Figure 2.  Reactive astrocytes co-localize with Congophilic plaques in APP+PS1 mice. 
Horizontal sections were immunostained using mAb 319 at a 1:5000 dilution, and then 
counterstained with Congo red.  Micrographs show the molecular layer of the CA3 region 
of the hippocampus.  Black staining of the cell bodies is clearly defined, with faint 
staining of processes, all surrounding the red plaque core.    Scale bar = 50 µm. 
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To determine if α7 expression by reactive astrocytes was due to a generalized 
inflammatory response to amyloid, we injected LPS into the hippocampus of APP and 
nontransgenic mice.  LPS treatment resulted in a diffuse pattern of mAb 319 
immunolabeling of astrocytes, cells known to react to LPS injections (Hauss-Wegrzyniak 
et al., 1998).   No changes were seen in neuronal staining with mAb 319 (Fig. 3).  Shown 
are the CA3 regions of saline injected (panels A,C) versus LPS injected mice (panels 
B,D).  A few immunopositive astrocytes were seen in saline treated APP mice (panel C), 
but not in the nontransgenics (panel A).  Both nontransgenics (Fig. 3B) and APP (Fig. 
3D) mice showed reactive α7 immunopositive astrocytes upon LPS treatment. 
 
Figure 3.  LPS stimulates astrogliosis and immunolabeling by anti-α7 antibodies.  
Nontransgenic (A,B) and APP (C,D) mice were injected with saline (A,C)  or LPS (B,D) 
7 days prior to sacrifice.  Horizontal sections were immunostained using mAb 319 at a 
1:5000 dilution.  Micrographs show the CA3 region of the injected hippocampus.  
Pyramidal cells were intensely stained, located in the upper left corner of each panel. LPS 
treatment resulted in widespread activation of astrocytes which were immunolabeled by 
mAb 319 (B,D).  Scale bar = 50 µm.  Abbreviations:  NT = nontransgenic, APP = mutant 
amyloid precursor protein transgenic, LPS = lipopolysaccharide. 
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Figure 3.  LPS stimulates astrogliosis and immunolabeling by anti-α7 antibodies. 
 25 
In a final set of experiments, LPS was injected into α7 null mice, thus testing the 
specificity of the anti-α7 antibodies.  Mice carrying a null deletion for α7 were genotyped 
and selected to be either nontransgenic (α7+) or homozygous null (α7-).  Genotyping 
results indicated a single band at 440 bp (α7+) or 750 bp (α7-).  Figure 4A shows typical 
PCR product banding for nontransgenic and null genotypes.  All mice were genotyped 
and sorted based on these results.  Subsequently, RNA was extracted from the 
hippocampus, reverse transcribed, and subjected to PCR to determine whether α7 mRNA 
was expressed.  Mice that had been genotyped as α7-, did not express α7 mRNA.  
Typical samples are shown in Figure 4B, with a positive signal at 381 bp in lane 1 
(nontransgenic), as well as a smaller primer-dimer product running at the end of the gel 
(present even in the absence of cDNA).  All animals genotypically α7+ also had α7 
mRNA; none of the α7 null mutant mice had α7 mRNA.   
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Figure 4.   Genotyping and RNA analysis of α7+ and α7- mice.  Panel A shows a typical 
PCR product with ethidium bromide/UV detection of genomic DNA.   Lanes 1-2 are 
from an α7+ mouse, showing only a 440 bp band in lane 1 indicating the wild type allele, 
but no band for the neo-cassette primers in lane 2.  Lanes 3-4 are from a homozygous null 
mutant α7- mouse, lacking the band for the wild type primers in lane 3, showing only a 
750 bp band indicating the neo-cassette disrupted allele in lane 4.  Panel B shows a 
typical RT-PCR product derived from mRNA and detected with ethidium bromide/UV.  
Both lanes show a small product due to primer-dimer formation.  Lane 1 shows a single 
specific band of the expected size of 381 bp from an α7+ mouse.  Lane 2, from a 
homozygous null mutant α7- mouse, shows no specific bands. 
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Immunohistochemistry was performed using tissue from both α7+ and α7- mice, 
with or without LPS injection.  Three different commercially available antibodies were 
used (Table 1).  Shown in Figure 5 are three anti-α7 antibodies (mAb 319 in panels A-B; 
mAb 306 in panels C-D; pAb H-302 in panels E-F).  Each antibody showed intense, 
ubiquitous labeling of neurons throughout the brain; cortical neurons are shown in this 
figure.  No difference in the staining patterns was seen between untreated α7+ (Panels 
A,C,E) and α7- mice (Panels B,D,F).  All three antibodies immunolabeled neurons in 
both genotypes.  LPS injection into the hippocampus caused reactive astrogliosis similar 
to that seen in Figure 3 (data not shown).  Again, mAb 319 labeled astrocytes in both α7+ 
and α7- mice.  Astrocytes were not labeled by mAb 306 nor pAb H-302 in either 
genotype or treatment.  Thus, regardless of treatment or antibody used, both α7+ and α7- 
mice showed distinct nonspecific labeling of neurons (mAbs 306, 319, pAb H-302) as 
well as astrocytes (mAb 319).   
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Figure 5.  Immunohistochemical analysis of α7+ and α7- tissue.  Horizontal sections 
were immunohistochemically analyzed using various anti-α7 antibodies.  Micrographs 
show neurons in the frontal cortex.  Ubiquitous staining of cell bodies was seen with all 
antibodies.  Some cytoplasm and processes are stained with mAb 306 (C-D, 1:3000 
dilution) and pAb H-302 (E-F, 1:200 dilution).  mAb 319 primarily stained neuronal cell 
bodies and nuclei (A-B, 1:5000 dilution).  Neurons in both α7+ (A,C,E) and α7- tissue 
(B,D,F) were immunolabeled by these anti-α7 antibodies.  Scale bar = 50 µm. 
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Antibody staining patterns were also examined by Western blot, using cortical 
tissue from both genotypes, with or without LPS injection.  The exposure times were 
increased to maximize detection of faint bands.  Although most antibodies showed many 
nonspecific bands, no antibody revealed differences in protein bands in untreated α7+ 
versus α7- mice at the expected molecular weight of 56 kDa (Fig. 6).  LPS injection 
caused upregulation of an unknown protein in both α7+ and α7- mice at approximately 45 
kDa (mAb 306) and 75 kDa (mAb 306, pAb H-302).  No additional bands were seen with 
mAb 319 after LPS treatment.  However, none of the antibodies detected differences 
between LPS treated α7+ versus α7- mice. 
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Figure 6.  Western blot analysis of α7+ and α7- tissue.  Cortical tissue was 
homogenized, subjected to SDS-PAGE, transferred and immunoblotted.  ECL detection 
was captured with subsequent film exposure.  The scanned image shown contains typical 
samples of alternating lanes of α7+ tissue and α7- tissue.  Tissues from both untreated 
control mice and LPS injected mice were run for each genotype and antibody. A primary 
band at 45 kDa, and a secondary band at 30 kDa was seen with mAb 319 (lanes 1-4).  
Strong bands at 30, 50, and 75 kDa were seen with mAb 306 (lanes 5-8).  Strong bands at 
30, 45, 75, and 100 kDa were evident with pAb H-302 (lanes 9-12).  Both nontransgenic 
α7+ and null mutant α7- tissue were immunolabeled by these anti-α7 antibodies.  LPS 
treatment resulted in an increase in immunolabeling by mAb 306 (bands at 50 and 75 
kDa) and pAb H-302 (bands at 75 kDa).  This increase in staining was seen in both α7+ 
and α7- tissue. 
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Discussion 
Three different commercially available antibodies intended to label α7 nAChR 
subunits were used in standard immunohistochemical and immunoblotting protocols. The 
antibodies were generated using different host species, and different α7 subunit 
sequences, though all products are directed towards portions of exon 10.   
Previous reports have shown the utilization of monoclonal antibodies from clones 
306 and 319 for immunohistochemical analysis of rat brain (Dominguez del Toro et al., 
1994).  The results reported by Dominguez del Toro indicated ubiquitous neuronal 
expression, similar to what we saw in our studies.  Both the Dominguez del Toro 
procedure and ours used paraformaldehyde fixation of the brain prior to sucrose 
cryoprotection.  Both procedures used 25 µm free floating sections, an avidin-biotin-
peroxidase protocol, and DAB color development.  The immunohistochemical protocols 
used in our experiments were developed to yield significant positive stain while 
minimizing background.  Various concentrations and combinations of primary (1:100-
1:10000) and secondary antibodies (1:1000-1:10000) were tested in an effort to identify 
conditions that stained the α7+/+, but not the α7 null mice, without success.  Tissue 
perfusion (saline versus paraformaldehyde) and post fixation times (2-24 hr) were also 
evaluated separately in nontransgenic α7+ mice.  No differences in the immunolabeling 
patterns were seen with any of these variations.  It is conceivable that the antigenic 
determinant(s) was modified by the paraformaldehyde treatment (Montero, 2003).  
Another possibility is that the levels of α7 may be so low, or the amount of antibody 
needed to yield a signal so high, that cross-reacting protein binding masked any α7 
positive cells. Other researchers that have worked with the α7 null mice did not use 
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immunohistochemistry to demonstrate the absence of this receptor, but rather showed the 
absence of α-bungarotoxin binding (Orr-Urtreger et al. 1997; Franceschini et al., 2002; 
Wang et al., 2003).  Using our paraformaldehyde treated tissue, we failed to detect 
specific labeling using fluorophore conjugated α-bungarotoxin (data not shown).   
The immunolabeling of reactive astrocytes in amyloid depositing mice by mAb 
319 was an interesting finding of these studies.  Subsequent studies with LPS injection in 
α7 knockout mice revealed this labeling to be nonspecific.  Recent reports by Teaktong 
and colleagues (2003) showed immunolabeled α7+ astrocytes in human AD brain.  
Cholinergic signaling by rat astrocytes has also been demonstrated (Sharma and 
Vijayaraghavan, 2001).  Activation of these cells produced calcium flux that was blocked 
by α-bungarotoxin, indicating the presence of α7 nAChRs.  The potential for some of the 
astrocyte α7 labeling to be specific should not be ruled out.  Thus, in designing 
experiments to evaluate α7 expression an alternative approach would be the use of α-
bungarotoxin instead of anti- α7 antibodies.  However, we were unable to develop 
adequate α-bungarotoxin labeling in formaldehyde fixed sections. 
Several reports have demonstrated Western blot analysis of α7 in rodent brain 
extracts using monoclonal antibodies from clones 306 and 319 (Schoepfer et al., 1990; 
Dominguez del Toro et al., 1994; Orr-Urtreger et al., 1997; Dineley et al., 2001; Fabian-
Fine et al., 2001).  These reports have listed the apparent molecular weight of the α7 
subunit ranging from 48-72 kDa, though the calculated molecular weight is 56 kDa.  
Some of the investigators used standard homogenization procedures, SDS-PAGE 
separation, transfer, and subsequent immunoblotting, similar to the procedure described 
here.  Other investigators affinity purified the α7 nAChRs with cobratoxin or 
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bungarotoxin prior to SDS-PAGE, resulting in a primary band at approximately 56 kDa 
(Dominguez del Toro et al., 1994; Orr-Urtreger et al., 1997).  The immunoblotting 
protocols used in our laboratory were developed to minimize nonspecific bands and 
background.  Various concentrations and combinations of primary and secondary 
antibodies, ranging from 1:50-1:10000, were tested in an effort to come up with 
conditions that differentiated between the α7+ and the α7 null mice, without success.  
Separately, various homogenization buffers (10 mM HEPES ± 1-2% triton-x 100, 50-150 
mM PBS ± 1-2% triton-x 100, 50 mM TBS ± 1-2% triton-x 100), vendors of secondary 
antibodies (Vector, Santa Cruz),  blocking solutions (BST + 2.5-5% milk, TBST + 2.5-
5% milk), and subcellular fractionation preparations ( crude, membrane, and solubilized 
fractions) were tried, but failed to reveal differences in the staining pattern between α7+ 
and α7 null mice.  Other researchers that have performed Western blot analysis of α7 null 
tissue did not use commercially-available antibodies, and also affinity purified the α7 
subunit prior to analysis (Orr-Urtreger et al. 1997; Franceschini et al., 2002; Wang et al., 
2003).  Again, an alternative approach in designing experiments to evaluate α7 
expression would be the use of α-bungarotoxin affinity purification.  However, the large 
amounts of tissue needed for affinity purification complicate the procedure and preclude 
analysis of small brain regions (such as the hippocampus) in individual rodents.   
There have been reports of a partial duplication of the human α7 nAChR gene, 
which has four novel N-terminus exons and conserved exons 5-10 (Gault et al., 1998; 
Villiger et al., 2002).  Such duplication has not been reported in rodents, but cannot be 
completely ruled out.  If there were such duplication, it might account for the α7 protein 
detection in the absence of α7 gene expression.  Still, one would expect at least a 
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quantitative difference in the amounts of stained material.  Alternatively spliced α7 
mRNAs have also been shown in mice (Saragoza et al., 2003).  The resultant mRNA 
includes a novel exon 9b.  Additionally, another splice variant with novel exon 4b has 
been reported in rat (Severance et al., 2004).  The Saragoza variant could potentially 
interfere with our RNA analysis, as the primers are designed to prime to exons 9-10.  In 
contrast, the Severance variant does contain exons 9-10 and should be eliminated in the 
knock out mouse.  However, alternatively spliced mRNAs would have no effect on the 
genotyping results as exons 8-10 are interrupted in the knock out.  Moreover, the 
complete absence of α7 mRNA in the null mice would require some mutation in any 
duplicated α7 gene which would disrupt the primer pairs from annealing.  We find such 
circumstances unlikely to account for the results we have obtained here. 
In conclusion, careful examination of protocols will be required in order to draw 
any conclusions made from immunodetection studies of α7 nAChRs.  Localization of the 
α7 subunit with immunohistochemistry must be interpreted with caution.  Confirmation 
with α-bungarotoxin binding experiments is recommended, as well as RNA analysis 
where applicable. 
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Chapter 2 
Acute and Chronic Microglial Inflammatory Responses After 
Intrahippocampal Administration of Lipopolysaccharide 
Abstract 
Inflammation has been argued to play a primary role in the pathogenesis of 
neurodegeneration in Alzheimer’s disease.  The inflammatory response can be either 
beneficial or harmful, depending particularly upon the duration of the reaction. 
Lipopolysaccharide (LPS) activates the innate immune response and triggers gliosis when 
injected into the central nervous system.  In studies described here, we evaluated the time 
course of microgliosis after acute intraparenchymal administration of LPS.  Mice were 
injected bilaterally into the hippocampus with 4 µg of LPS. Post injection survival times 
were 1, 6, and 24 hr, as well as 3, 7, 14, and 28 days. Protein and RNA analyses were 
performed for inflammatory markers.   Significant elevations of cluster differentiation 
marker CD45, glial fibrillary acidic protein (GFAP), scavenger receptor A (SRA), and 
Fcγ receptor mRNA were seen after 24 hr.  Immunohistochemistry revealed a complex 
pattern of protein expression by microglia coupled with changes in morphology.  RNA 
and protein for Fcγ receptor, GFAP, and SRA were transiently elevated, peaking at 3 
days, and returned to basal levels after a week.  In contrast, microglia remained 
significantly activated through the 28 day time point as determined by CD45 and 
complement receptor 3 levels. These findings indicated that the inflammatory response 
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had both an acute and chronic response to LPS that was mediated primarily by microglia 
in the central nervous system. 
Introduction 
Neuroinflammation is a consistent pathological event in many neurodegenerative 
diseases including Alzheimer’s disease (AD).  AD is of particular interest due to several 
epidemiological studies implicating NSAID use with lower levels of AD risk (McGeer & 
McGeer, 1996; In ‘t Veld et al., 1999). The inflammatory response of the periphery is 
well characterized, but until recently, the brain was considered a privileged organ, 
without much of an immuno-inflammatory system.  We now know that the resident 
macrophages of the brain, microglia, coordinate local inflammation as well as the innate 
immune response (Streit, 2002).  The inflammatory response in AD encompasses 
components of the complement system, cytokines and chemokines, reactive oxygen 
species, prostaglandins, and a host of others (Akiyama et al., 2000). 
Lipopolysaccharide (LPS) has traditionally been used to stimulate the innate 
immune response.  LPS is a Gram-negative bacterial cell surface proteoglycan, also 
known as bacterial endotoxin, which triggers an inflammatory response by the host.  LPS 
binds to circulating LPS binding protein, which subsequently transfers the LPS to 
membrane bound cluster differentiation (CD) marker CD14, a common receptor for 
bacterial components (Heumann & Roger, 2002).  The CD14 protein does not contain an 
intracellular domain, so interaction with additional components is likely.  Toll like 
receptor 4 (TLR4), as well as myeloid differentiation protein (MD2), form a complex 
through which LPS:CD14 can transduce a signal (Thomas et al., 2002).  Multiple 
cascades are involved in the signal transduction, with nuclear factor NFκB as a key 
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player.  Downstream gene activation triggers the production of cytokines, nitric oxide, 
and prostanoids leading to the cellular inflammatory response. 
The role of inflammation in the brain is controversial.  The phagocytic 
capabilities of microglia have been exploited in amyloid depositing transgenic mice, 
aiding in the removal of Aβ deposits during passive immunization (Wilcock et al., 2003, 
2004a,b) as well as after activation of the innate immune system (DiCarlo et al. 2001, 
Herber et al., 2004b).  However, the ability of activated glia to produce cytokines, 
chemokines, and other noxious products may lead to neuronal damage.  Many in vitro 
studies have demonstrated that LPS-stimulated microglia cause neuron death (Chao et al., 
1992; Kim et al., 2000; Lehnardt et al., 2002).  However, only under chronic activation in 
vivo has LPS been shown to induce enough inflammation to cause basal forebrain 
neurodegeneration (Hauss-Wegrzniak et al., 2002).  An exception is the acute injection of 
LPS into the substantia nigra, which caused cell death, possibly due to the high ratio of 
microglial per neuron in that brain region (Kim et al., 2000). 
In our studies, we have combined traditional immunohistochemistry with 
quantitative real time polymerase chain reaction (qRT-PCR) to better understand the 
inflammatory response to LPS in the brain.  We injected LPS into the hippocampus of 
young mice and subsequently measured mRNA and protein for markers of inflammation 
and phagocytosis.  We demonstrate the time course of this response, and the involvement 
in particular of microglia.   
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Materials and Methods 
Mouse Strains 
Nontransgenic mice obtained during the breeding of our APP+PS1 transgenic 
mouse colony (Holcomb et al, 1998) aged 5-6 months were used in this study, with 6 
animals per experimental time point, for a total of 48 mice.  Animals were group-housed 
under a 12 hr light-dark cycle with free access to chow and water. Experimental groups 
were balanced regarding gender. 
Intrahippocampal Injections 
Mice were anesthetized using isoflurane and immobilized in a stereotaxic 
apparatus.  One microliter injections of 4 µg/µl lipopolysaccharide (Salmonella abortus 
equi, Sigma, Saint Louis, MO) were delivered over a two minute period into both 
hippocampi (stereotaxic coordinates from bregma: -2.7 mm posterior; +/-2.5 mm lateral; 
-3.0 mm ventral).  This procedure had been previously demonstrated in our lab to induce 
a neuroinflammatory response without adversely affecting animal survival or causing 
neurotoxicity (DiCarlo et al., 2001).  The control group consisted of untreated mice. LPS 
treated mice survived 1, 6, 24, 72, 168, 336, or 672 hr post injection. Animals were singly 
housed for the post treatment survival period under standard vivarium conditions.  All 
animal work was conducted under National Institute of Health guidelines, and approved 
by the University of South Florida’s institutional animal care and use committee.    
Tissue Preparation 
Mice were anesthetized with pentobarbital (200 mg/kg, ip), then perfused 
transcardially with 25 ml of saline.  The brain was removed, the right hippocampus was 
dissected, and the tissue was then stored at –80°C for subsequent biochemical analyses.  
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For immunohistochemistry, left hemispheres were transferred into a 4% neutral buffered 
paraformaldehyde solution for 24 hr, then processed through a cryoprotection schedule of 
10, 20, then 30% sucrose (24 hr in each solution).  The tissue was sectioned horizontally 
on a sliding microtome at 25 µm.  Sections were then stored in Dulbecco’s phosphate 
buffered saline pH 7.4 (DPBS) with sodium azide (100 mM) at 4°C. 
RNA Analysis 
Tissue from the right hippocampus was analyzed for mRNA expression via 
reverse transcription followed by qRT-PCR, as described by Dickey and colleagues 
(2003).  RNA was extracted from the injected hippocampus using Qiagen’s Rneasy® 
procedure (Valencia, CA).  The hippocampus was homogenized in 700 µl of RLT buffer 
for 30 seconds using an electronic rotor-stator.  The manufacturer’s protocol for RNA 
preparation was followed as indicated, including the optional on-column DNAse 
digestion.  Sample RNA was then assayed using Molecular Probes RiboGreen® RNA 
quantitation kit (Molecular Probes, Eugene, OR).  A series of standard RNA solutions 
were prepared ranging from 20-1000 ng/µl.  Samples and standards were prepared in 
triplicate, using 1 µl of sample per 200 µl reaction volume.  Fluorescence was monitored 
at 485 nm excitation and 538 nm emission wavelengths.  Each sample RNA was then 
diluted in water to a final concentration of 50 ng/µl and 5 ng/µl.  The 50 ng/µl samples 
were run on a 1% agarose gel using ethidium bromide/ultraviolet detection.   
A composite of all RNA samples was made in order to prepare a standard curve 
for qRT-PCR analysis.  A pool consisting of 2 µl of each 50 ng/µl sample was made.  
Serial dilutions of this composite standard were made down to 0.2 ng/µl to construct a 
standard curve.  Reverse transcription (RT) with mMLV (Invitrogen, Carlsbad, CA) was 
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then performed on the standard dilutions and 5 ng of each sample RNA solution, using 
the master mix and conditions detailed in Table 2.  The resulting cDNA was then 
subjected to qRT-PCR using SYBR® Green PCR Master Mix (Molecular Probes, 
Eugene, OR).  Table 3 contains the primer sequences and cycling conditions used in the 
PCR reaction.  The sequence for scavenger receptor B is identical to that listed for CD36 
as listed in GenBank; note that the same sequence is listed for SR-B1 and various other 
pseudonyms.  For each reaction, 12.5 µl of SYBR Green, 7.5 µl water, 1.5 µl of each 
primer, and 2 µl of the 5 ng sample dilutions were run using an MJ Research DNA 
Engine™ Cycler with Opticon™ Detector (MJ Research, Inc., Waltham, MA).  
Quantitation of several mRNAs was performed using the cDNA generated by reverse 
transcription. 
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Table 2.  Reverse Transcription Master Mix and Cycling Conditions 
 
Master mix  
reagent 
Stock 
concentration 
Source µl per 
reaction 
 
Water 
 
- 
 
- 
 
3.875 
 
MgCl2 25 mM Sigma 4 
 
Random hexamers 500 µg/ml Integrated DNA  
Technologies (IDT) 
0.5 
 
 
Oligo DT 500 µg/ml IDT 0.5 
 
dNTPs 10 mM Invitrogen 1 
 
Buffer 5x Invitrogen 1 
 
DTT 0.1 M Invitrogen 2 
 
Betaine 5 M Sigma 6 
 
Reverse transcriptase 200 U/µl Invitrogen 0.125 
 
Sample RNA 5 ng/µl - 1 
 
 
Cycling Conditions 
 
1) 25°C for 10 min 
2) 42°C for 30 min 
3) 60°C for 30 min 
4) 95°C for 5 min 
5) 4°C for storage 
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Table 3.  Primer Sequences for qRT-PCR 
 
Target Primer Pairs 
  
Cluster differentiation marker  
(CD14) 
F: 5’-GGAACATTTGCATCCTCCTG-3’ 
R: 5’-TGAGTTTTCCCCTTCCGTGT-3’ 
 
Cluster differentiation marker  
(CD45) 
F: 5’-CAGAGCATTCCACGGGTATT-3’ 
R: 5’-GGACCCTGCATCTCCATTTA-3’ 
 
Fc gamma receptor IIb 
(FcγRIIb) 
F: 5’-GGAAGAAGCTGCCAAAACTG-3’ 
R: 5’-CCAATGCCAAGGGAGACTAA-3’ 
 
Glial fibrillary acidic protein 
(GFAP) 
F: 5’-GATCGCCACCTACAGGAAAT-3’ 
R: 5’-GTTTCTCGGATCTGGAGGTT-3’ 
 
Interleukin 1 beta 
(IL1β) 
F: 5’-CTCATTGTGGCTGTGGAGAA-3’ 
R: 5’-GCTGTCTAATGGGAACGTCA-3’ 
 
Ribosomal RNA 18S subunit 
(18S rRNA) 
F: 5’-GTAACCCGTTGAACCCCATT-3’ 
R: 5’-CCATCCAATCGGTAGTAGCG-3’ 
 
Scavenger receptor A 
(SRA) 
F: 5’-GACGCTTCCAGAATTTCAGC-3’ 
R: 5’-ATGTCCTCCTGTTGCTTTGC-3’ 
 
Scavenger receptor B 
(SRB) 
F: 5’-AAGTGGTCAACCCAAACGAG-3’ 
R: 5’-ACTTGTCAGGCTGGAAATGG-3’ 
 
Synaptotagmin F: 5’-CATCGACCAGATCCACTTGT-3’ 
R: 5’-TCGTTTCCTACTTGGCACAC-3’ 
 
Toll like receptor 4 
(TLR4) 
F: 5’-GCCGGAAGGTTATTGTGGTA-3’ 
R: 5’-AGGCGATACAATTCCACCTG-3’ 
 
Tumor necrosis factor alpha 
(TNFα) 
F: 5’-CTGTGAAGGGAATGGGTGTT-3’ 
R: 5’-CCCAGCATCTTGTGTTTCTG-3’ 
 
  
Cycling Conditions 
 
 
1) 95°C for 15 min 
2) 95°C for 15 sec 
3) 60°C for 60 sec 
4) Plate read 
5) Go to line 2,  39 more times 
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The SYBR Green reaction occurs when the dye binds to double stranded DNA.  
Maximum absorbance is 497 nm, with emission at 520 nm.  The Opticon instrument is 
compatible with a 96 well format, and uses individual excitation and detection of each 
well.  For each mRNA of interest, a melt curve analysis of the PCR product was 
performed after cycling was complete.  Fluorescence was read in 1°C increments from 
56-99°C. Primer pairs were designed to yield a single, specific product, with no evidence 
of primer-dimer formation using Primer 3 software from the MIT web site 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.  The following rules were helpful in 
primer design: 50% GC content, 18-30 bases long (20 optimal), identical predicted 
melting temperatures of both primers (optimal is 60°C), verify no self complementarity 
or primer-dimer  formation (additional information on potential primer-dimer is available 
from Qiagen on the Web at http://oligos.qiagen.com/oligos/toolkit.php - no run of more 
than 3 bases annealing between primers), avoid 3 or more G or C bases at 3’ end of 
primers, and target a product size between 100-300 bp.  All primers were checked for 
target specificity using the NCBI homepage at http://www.ncbi.nlm.nih.gov/BLAST/ . 
The Quantity Calculations derived by the Opticon MONITOR™ Analysis 
Software (version 1.07) yeild the cycle number at which the fluorescence exceeds the 
background level, called the C(T) value.  In general, the lower the C(T) value, the higher 
number of cDNA copies in the sample.  For each mRNA of interest, the C(T) values from 
the PCR were determined.  To create a linear curve, the log of ng RNA in each standard 
was plotted against the average C(T) value (each sample and standard was analyzed in 
triplicate).  Log ng RNA were calculated for each sample, and then converted to ng RNA.  
For a given reverse transcription, all targets of interest were normalized to results for 18S 
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rRNA for the same sample to control for variations in the starting RNA concentration and 
enzyme efficiency.  The ratio of the ng target RNA to ng 18S rRNA was calculated, and 
the results subjected to one way analysis of variance (ANOVA), followed by Fisher’s 
protected least squares difference (PLSD) with significance taken at p < .05.  The final 
results are presented as fold change versus control mice. 
Histology 
Immunohistochemical analysis of reactive glial markers was performed using four 
25 µm free-floating sections spaced 300 µm apart through the hippocampus.  Details of 
this procedure were originally described elsewhere (Gordon et al., 1997).  Sections were 
first blocked for endogenous peroxidases  (10% methanol, 3% hydrogen peroxide in 
DPBS) for 15 minutes, washed with DPBS, then permeabilized in a solution of 100 mM 
lysine, 0.2% triton x-100, and 4% normal goat or horse serum (Pel Freeze, Rogers, AK) 
in DPBS for 30 minutes.  Sections were then incubated overnight in the appropriate 
primary antibody in DPBS and 4% serum (Table 4).  The following day, sections were 
washed with DPBS, and then incubated in appropriate biotinylated secondary antibody 
(Vector Laboratories, Burlingame, CA) at a concentration of 0.5 µg/ml in DPBS and 4% 
serum, for two hours.  Sections were washed with DPBS, and then incubated for one hour 
in Vectastain® Elite® ABC solution (Vector Laboratories, Burlingame, CA).  Sections 
were then washed and incubated with a solution of 0.5% nickelous ammonium sulfate 
hexahydrate and 0.05% diaminobenzidine in tris buffered saline for 5 minutes.  Color 
development was achieved by the addition of 0.03% hydrogen peroxide, and incubation 
for an additional 5 minutes, followed by washes.  Controls for nonspecific binding of the 
secondary antibody were performed by excluding primary antibodies.  GFAP 
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immunostaining was performed using horseradish peroxidase-streptavidin (Vector 
Laboratories, Burlingame, CA) at 1 µg/ml, rather than ABC and nickel enhancement was 
not used.  Sections were slide mounted and cover slipped, then imaged at 100x 
magnification, focusing on the dentate gyrus of the hippocampus.  Images were then 
analyzed for area percent positive stain using Image-Pro® Plus software 
(MediaCybernetics, Silver Spring, MD).  The results were subjected to one way 
ANOVA, followed by Fisher’s PLSD with significance taken at p < .05.  The final results 
are presented as fold change versus control mice. 
 
Table 4.  Primary Antibodies Used for Immunohistochemistry 
 
Antigen Antibody Type Source Catalog # Titer 
     
CD45 
 
Rat monoclonal 
 
Serotec MCA1031G 1:3000
CR3 (CD11b) 
 
Rat monoclonal 
 
Serotec MCA711 1:3000
FcγRII/III 
 
Rat monoclonal 
 
PharMingen 553141 1:3000
GFAP 
 
Rat monoclonal 
 
Zymed 13-0300 1:3000
TLR4 Rabbit polyclonal Imgenex IMG-579 1:3000
     
 
Results 
LPS was injected into the hippocampus of nontransgenic mice and a time course 
established for both RNA and protein expression of inflammatory markers.  Animal 
health overall was mildly affected by LPS.  Some weight loss was seen, which was 
significant after 7 days, but returned to normal beginning at 2 weeks.  Malaise was only 
notable at the 24 hr time point, primarily evidenced by hypo-locomotion. 
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Advantages of RNA analysis by qRT-PCR include accurate quantitation of 
several markers from very small samples and assessment of specific isoforms, even when 
suitable antibodies are not available for immunohistochemistry.  Figure 7A shows a 
typical standard curve generated for Ribogreen assay of sample RNA concentrations.  All 
samples were within the linear range of the assay, averaging 65 ng of RNA per µl of 
sample extract.  Figure 7B shows typical ethidium bromide/UV detection of the RNA.  
All samples were intact, with no evidence of RNA degradation.  Samples at a 
concentration of 5 ng/µl in water, as well as standards spanning 0.2-50 ng/µl in water, 
were subjected to qRT-PCR.  Melt curve analysis of the PCR product indicated a single 
specific reaction product.  An example of a typical melt curve is shown in Figure 7C.  A 
single peak without shoulders or evidence of multiple peaks indicated specific primer 
annealing.  The standard curves for the qRT-PCR were then generated, as shown in 
Figure 7D.  All targets had correlation coefficients of not less than 0.95, with less than 
25% variability in the slopes between the curves for different target mRNAs (for 
example, comparing 18S to IL1β).  The slope represents the efficiency of the PCR 
reaction for the particular primer pair used.  Less than 10% variation would be necessary 
to detect more subtle changes in gene expression as variations in the efficiency of the  
PCR of the target compared to 18s could artificially bias the result.  
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Figure 7.  mRNA analysis by qRT-PCR.  RNA from the hippocampi of LPS injected mice 
was extracted and assayed.  Panel A shows the standard curve used for RiboGreen® 
estimation of total RNA levels.  Panel B shows the typical ribosomal banding pattern of 
50 ng total RNA samples, indicating the absence of significant degradation.  After 
reverse transcription, cDNA was subjected to qRT-PCR.  Panel C shows the melt curve 
for 18s rRNA qRT-PCR product, typical of all primers used.  A single peak without 
shoulders indicated specific priming.  Panel D shows a standard curve generated for the 
18s rRNA qRT-PCR, plotting mass of the RNA added to the reverse transcription versus 
the threshold cycle C(T).  All primers used in this work generated a standard curve with 
slopes varying by less than 25%. 
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A time course was established for LPS stimulated gene transcription.  Figure 8A 
contains cell-specific markers.  The glial markers CD45 and GFAP both changed their 
expression over time, whereas synaptotagmin did not change (F(8,45) = 25, p < .0001; 
F(8,45) = 35, p < .0001; F(8,45) = 1.2, p = .30, respectively).  Post hoc analysis revealed 
significant differences compared to untreated control mice, with significance taken at 
p < .05.  The microglial marker CD45 was significantly elevated by 6 hr, peaked at 3 
days (72 hr), and remained elevated throughout the time course to 28 days (672 hr) post 
injection.  GFAP followed a similar time course and increased significantly from 6 hr to 7 
days (168 hr), but returned to baseline by 14 days (336 hr).  Figure 8B shows results for 
three receptors involved in phagocytosis.  Scavenger receptor A (SRA), scavenger 
receptor B (SRB), and Fcγ receptor IIb (FcγRIIb) all changed expression over time (F(8,45) 
= 9.5, p < .0001; F(8,45) = 6.4, p < .0001; F(8,45) = 25, p < .0001 respectively).  Post hoc 
analysis revealed significant differences compared to untreated controls, with 
significance taken at p < .05.  SRA was significantly elevated by 6 hr, peaked at 3 days, 
and then dramatically declined by 14 days.  In contrast, SRB was briefly and modestly 
elevated only at the 6 hr time point, otherwise remaining unchanged. The FcγRIIb 
followed a similar time course to SRA, but remained modestly elevated out to 28 days.   
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Figure 8.  Time course of mRNA expression.  RNA from the hippocampus of mice 
injected with LPS and allowed to survive 1 hr, 6 hr, 24 hr, 72 hr (3 days), 168 hr (7 days), 
336 hr (14 days), and 672 hr (28 days), was subjected to qRT-PCR.  Results are presented 
as mean ± SEM of fold change compared to untreated control mice (n=6 each group). 
Note that the x-axis is not linear in order to permit evaluation of both early and late time 
points.  Panel A shows the cell specific markers CD45 (microglia), GFAP (astrocytes), 
and synaptotagmin (neurons).  Both CD45 and GFAP levels peak around 3 days; only 
CD45 remained elevated at 28 days.  Synaptotagmin levels were unaffected by treatment.  
Panel B shows three receptors capable of mediating phagocytosis, SRA, SRB, and 
FcγRIIb.  SRA was transiently elevated, peaking from1-3 days .  FcγRIIb also peaked 
around 3 days, but remained modestly elevated at 28 days.  SRB had a small increase, 
significant only at 6 hr.  Panels C and D show results of RNA from the hippocampus of 
mice injected with LPS and allowed to survive 72 hr (3 days). Panel C shows significant 
increases in both TLR4 and CD14 messages.  Panel D shows dramatic increases in TNFα 
and IL1β messages; note greater than 30 fold increases of IL1β.    * p < .05 for all panels 
versus untreated controls. 
 
 50 
 
Figure 8.  Time course of mRNA expression. 
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Based on the findings that most of the target RNAs peaked at 3 days, several 
additional markers were examined at that time point.  Figure 8C shows the relative 
expression of two key components of the LPS signaling cascade, compared to untreated 
control mice.  Both the LPS receptor cluster differentiation marker (CD14) and toll like 
receptor (TLR4) were significantly elevated.  Figure 8D shows the relative contributions 
of interleukin (IL1β) and tumor necrosis factor (TNFα).  IL1β message was increased by 
greater than 30-fold.  TNFα was also significantly elevated, but to a lesser extent.  
Immunohistochemical analysis of horizontal brain sections was conducted to 
verify the cell-specific expression of several inflammatory markers identified by RNA 
analysis.  Figure 9 shows the time course of changes in expression for four microglial 
markers.  Representative micrographs from the site of LPS injection (the hilus of the 
dentate gyrus subregion of the hippocampus) are presented.    Untreated mice 
demonstrated resting, ramified microglia, with fine delicate processes which were marked 
by CD45 and complement receptor CR3 (Fig. 9A-D).  LPS treatment resulted in a 
widespread activation of microglia with a concurrent shift in morphology. After 1 hr (Fig. 
9E-H), cells increased expression of CD45, CR3, and Fcγ receptor II/III (FcγRII/III) and 
developed thicker, shorter processes; this increase was more obvious at 6 hr (Fig. 9I-L).  
By 24 hr, the increases were observable for all four markers CD45, CR3, SRA, and 
FcγRII/III (Fig. 9M-P).  The ramified microglia predominated at this time point, but 
small, rounded cells were also seen.  After 72 hr, the staining intensity was at its peak for 
all four markers.  Multiple morphologically distinct cells were visible including hyper-
ramified (bushy, indicated by arrow in Fig. 9S), round, and amorphous/ameboid cells 
with smaller numbers of thick processes (Fig. 9Q-T).  After a week, SRA and FcγRII/III 
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expression had subsided, but CD45 and CR3 remained high.  The bushy microglial 
morphology predominated (Fig. 9U-X).  An interesting finding was both CD45 and CR3 
continued to mark bushy, reactive microglial after 2 weeks (Fig. 9Y-BB) and 4 weeks 
(Fig. 9CC-FF). 
 
Figure 9.  Time course of microglial protein expression and morphology.  Brains from 
LPS injected mice were sectioned horizontally at 25 µm and immunostained.  Each row 
represents a different time point: untreated mice (A-D); LPS treated mice (E-FF) survived 
1 hr (E-H), 6 hr (I-L), 24 hr (M-P), 3 days (Q-T), 7 days (U-X), 14 days (Y-BB), and 28 
days (CC-FF).  Each column represents a different marker: the first column is CD45, the 
second column is CR3, the third column is SRA, and the fourth column is FcγRII/III.  
Micrographs are from the hilus of the dentate gyrus of the hippocampus.  Resting 
microglia are seen after saline treatment (A-D), expressing CD45 (A) and CR3 (B).  
From 1 hr (E-H) to 6 hr (I-L) cells became swollen and increased levels of CD45 (E,I), 
CR3 (F, J) and FcγRII/III (H,L) are apparent.  By 24 hr (M-P), all four markers are 
expressed, on both round and ramified cells.  At 3 days, expression levels are peaking, as 
round, ameboid, and ramified/bushy cells stain intensely for CD45 (Q), CR3 (R), SRA 
(S), and FcγRII/III (T).  The arrow in Panel S indicates a bushy morphology.  At 7 days 
(U-X), 14 days (Y-BB), and 28 days (CC-FF), SRA (W, AA, EE) and FcγRII/III 
(X,BB,FF) decrease to control levels; CD45 (U,Y,CC) and CR3 (V, Z, DD) remained 
elevated.  Scale bar = 50 µm. 
 53 
 
 
Figure 9:  Time course of microglial protein expression and morphology. 
 54 
Semi-quantitative results for microglial immunohistochemical analyses in the 
dentate gyrus are shown in Figure 10.  CD45, CR3, SRA, and FcγRII/III all changed 
significantly over time (F(8,45) = 11.4, p < .0001 F(8,45) = 12.3, p < .0001 F(8,45) = 3.4, p = 
.0037 F(8,45) = 4.4, p = .0006, respectively).  Post hoc analysis revealed significant 
differences compared to untreated control mice, with significance taken at p < .05. 
Results are expressed as fold change versus untreated controls.  Up to three fold increases 
in CD45 levels were seen, beginning at 1 hr and lasting to 28 days (Fig. 10A).  A similar 
profile for CR3 was obtained, with up to four-fold increases from 1-28 days (Fig. 10B).  
SRA, though significantly increased only at 1 and 3 days, showed over 30 fold change 
relative to the virtual absence of staining in control animals (Fig. 10C).  FcγRII/III 
staining was also transiently and significantly elevated at 1 and 3 days by 25 fold  
(Fig. 10D).   
 
Figure 10.  Quantitation of immunohistochemical results for microglial markers.  Brains 
from LPS injected mice were sectioned horizontally at 25 µm, and immunostained.  
Images were collected from the dentate gyrus of the hippocampus at 100x magnification.   
The percent area occupied by positive stain was calculated.  Results shown are fold 
change compared to uninjected mice.  Note that the x-axis is not linear in order to permit 
evaluation of both early and late time points. CD45 was significantly elevated from 1 hr 
out to 28 days.  CR3 displayed a similar time course, with significant increases from 1-28 
days.  In contrast SRA and FcγRII/III were transiently activated, with significant 
increases only at 1-3 days.  * p < .05.
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Figure 10.  Quantitation of immunohistochemical results for microglial markers. 
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Astrogliosis was also evaluated in response to LPS and is shown in Figure 11.  
Untreated mice showed detectable levels of GFAP in the hippocampus (Fig. 11A).  Three 
days after treatment, astrocytes throughout the injected hippocampus increase GFAP 
expression and had thickened processes (Fig. 11B).  Figure 11C shows the dentate gyrus 
results expressed as fold change of stained area compared to untreated controls.  A main 
effect of time was determined (F(8,45) = 8.2, p < .0001).  Post hoc analysis revealed 
significant increases beginning at 1 day, peaking from 3-7 days, and remaining modestly 
elevated at 28 days.  
 
Figure 11.  Time course of astrogliosis in response to LPS.  GFAP levels in the brains of 
LPS injected mice were demonstrated by immunohistochemistry.  Panel A depicts the 
hippocampus of an untreated mouse showing low, basal levels of GFAP.  Panel B shows 
the heightened astrocyte reaction 3 days after LPS injection.  Statistical analysis of the 
dentate gyrus subregion, shown in Panel C, revealed significant activation beginning at  
1 day, peaking from 3-7 days, then remaining moderately elevated out to 28 days.  The  
x-axis is nonlinear to show the changes at early time points.   
Scale bar = 500 µm.  * p < .05. 
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Figure 11.  Time course of astrogliosis in response to LPS. 
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Finally, Figure 12 presents the immunohistochemical results for TLR4.  
Representative micrographs of the dentate gyrus subregion of the hippocampus are 
shown.  No cellular staining for TLR4 was detectable in untreated animals (Fig. 12A).  
As early as 1 hr after injection, TLR4 immunostaining was evident as a band of staining 
along the inner extent of the granule cell layer of the dentate gyrus (Fig. 12B) as well as 
along the edge of the hippocampal fissure (not shown).  Beginning at 24 hr, punctuate 
staining was evident in the hilus (Fig. 12C).  Figure 12D shows the dentate gyrus fold 
change of stained area compared to controls.  Post hoc analysis revealed significant 
increases from 1-6 hr. This is due to the intense layer of stain seen in Figure 12B.  This 
layer of stain decreases over the first week, as punctuate stain starts to appear.  The 
increase in the punctuate stain, though visually discernible, was not statistically 
significant using the area measurement (p = .055 at 3 days; p = .077 at 7 days). 
 
Figure 12.  Time course of TLR4 levels after LPS injection.  Immunohistochemical 
analysis of TLR4 was conducted using 25µm horizontal brain sections from LPS treated 
mice.  Micrographs are representative of the dentate gyrus subregion of the hippocampus.  
Panel A shows an untreated mouse with little to no positive stain.  Panel B shows an 
intense layer of stain along the inner dentate granule cell layer, 1 hr after LPS injection.  
Panel C shows punctate and more dispersed stain in the hilus, beginning 3 days after 
injection.  Statistical analysis, shown in Panel D, revealed significant increases at 1 and  
6 hr, as well as smaller increases at 3 and 7 days.  The x-axis is nonlinear to show the 
changes at early time points.  Scale bar = 200 µm.  * p < .05. 
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Figure 12.  Time course of TLR4 levels after LPS injection.  
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Discussion 
 
Lipopolysaccharide is a prototypical inflammatory agent used in both the 
periphery and in the brain.  Here, we describe the time course of the microglial reaction 
to LPS in vivo.  RNA and protein data concur that there is an acute and chronic response 
to a single intrahippocampal injection of LPS. 
The acute reaction to LPS began as early as 1 hr post injection.  This short term 
response peaked at 3 days for both RNA and protein levels, returning to basal levels by 
about 7 days for several markers.  The response of astrocytes was demonstrated by 
increases in GFAP.  Several markers of the microglial response were also evaluated.  
Two key receptors that can mediate phagocytosis, FcγRII/III and SRA, were only briefly 
up-regulated, perhaps priming the system for either mounting an acquired immune 
response or continuing the innate response.  The endogenous ligand for Fcγ receptor is 
typically the Fc region of IgG.  However, there is no evidence in the current studies that 
anti-LPS antibodies were produced in the LPS-injected mice, although such a possibility 
cannot be ruled out.  On the other hand, it has been demonstrated that LPS can induce Fcγ 
expression in the absence of IgG, as part of cell activation.  In addition, Fc receptor 
expression by macrophages can be regulated by cytokines as well as by LPS (Amigorena 
et al., 1989; Lynch et al., 1990; Laszlo & Dickler, 1990; Loughlin et al., 1992; Keller et 
al., 1994).  Thus, it is likely that the induction of Fcγ reflects another facet of microglial 
activation and not the presence of specific immunoglobulin.   
Scavenger receptors play a key role in mediating innate immunity.  They are 
pattern recognition receptors, with bacterial and viral products as typical ligands, 
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including LPS.  It is interesting that fibrillar Aβ is also a ligand for SRA and SRB 
(Huseman et al., 2002).  Our lab has previously shown decreased levels of Aβ after 
intrahippocampal injection of LPS in amyloid depositing mice (Chapter 3 of this 
dissertation, Herber et al., 2004b; DiCarlo et al, 2001).  It is possible that LPS increased 
expression of SRA which promoted the removal of Aβ via phagocytosis in that study.  
We were surprised that we did not see large increases in SRB in the current study, which 
has been implicated in Alzheimer’s disease (Bamberger et al., 2003).  We only detected a 
33% increase in mRNA, and only at the 6 hr time point.  Appropriate antibodies were 
unavailable for immunohistochemical analysis, thus no protein data were collected. 
The chronic response to LPS was seen mainly in microglia, as demonstrated by 
both RNA and protein expression of CD45.  This was further confirmed by CR3 
immunohistochemistry.  Our data showed significant microgliosis 28 days after a single 
injection of LPS.  This confirms our earlier report using a similar protocol in amyloid 
depositing transgenic mice (Herber et al., 2004b).  Our results from the direct injection of 
LPS into the central nervous system are in contrast to L5 nerve transection, where CR3 
expression peaked at 14 days, but returned to baseline by 28 days (Tanga et al., 2004).  
Tanga and colleagues also showed a sustained response by GFAP to both nerve 
transection and to peripheral administration of LPS (Tanga et al., 2004; Raghavendra et 
al., 2004).  In our model, the GFAP response was largely resolved after 7 days.   
CD45 is a protein tyrosine phosphatase (reviewed in Irie-Sasaki et al., 2003).  It is 
thought that activation of CD45 leads to dephosphorylation of key proteins, allowing for 
a quick response upon subsequent stimulation. CR3 is an integrin that mediates cell 
migration, adhesion, and phagocytosis (reviewed in Ehlers, 2000).  CR3 can also bind 
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LPS and is involved with CD14 in the activation of NFκB.  The sustained elevation of 
CD45 and CR3 by microglia may reflect a hyper-reactive system, remaining primed for 
subsequent stimuli.  These same cells may also continue to produce cytokines and 
chemokines, creating a potentially hostile environment. 
Changes in microglial morphology and protein expression after LPS injection 
were complex.  Early in the time course (1-6 hr), we saw thickening and shortening of the 
cell processes as CD45, CR3 and Fcγ receptor expression increased.  By 24 hr, SRA 
expression was also seen on these bushy, hypertrophied cells.  Small round cells 
expressing CD45 and CR3 appeared at 24 hr, and an amorphous/ameboid cell form was 
at 3 days.  The three cell shapes, bushy, round, and ameboid coexisted at the 3 day time 
point and expressed all four markers.  Only the bushy phenotype persisted and only in 
cells expressing CD45 and CR3.  The significance of these cell shapes and their 
contribution to cell function has yet to be determined.  It is possible that the small round 
cells seen at 24 hr are actually peripheral monocytes that had entered the CNS after 
injection.  Montero-Menei and colleagues showed that as much as 80% of OX-42 (rat 
equivalent of CR3) and ED1 (CD68) positive cells present in the rat brain 24 hr after 
intracerebral LPS injection were attributable to recruited monocytes (1996).  Similar 
MHCII positive round cells have been reported 48 hr after intraventricular LPS injection 
in rats (Hauss-Wegrzyniak et al., 1998a,b).  This same report showed MHCII positive 
“bushy” cells 4-7 days post injection.  It is impossible to differentiate between brain and 
peripheral macrophages using current labeling techniques.  One is tempted to assume the 
round and/or ameboid cells are phagocytic.  Our own results in amyloid depositing 
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transgenic mice, showing decreased Aβ burden 3-14 days after LPS injection, suggests 
phagocytosis by some cell population (Herber et al., 2004b).   
Several additional markers of inflammation were investigated.  Increases in the 
RNA for cytokines IL1β and TNFα were expected after LPS administration (Kim et al., 
2000; Nadeau & Rivest, 2002; Raghavendra et al., 2004).  These cytokines not only 
prime the system but can also create a damaging environment.  Neurodegeneration was 
not detectable in our model using cresyl violet or fluorojade stains (data not shown).  Our 
observations of the level of inflammation in the brain indicated a spreading wave of 
microgliosis, using CR3 as a marker.  Untreated mice showed low levels of CR3 even in 
resting microglia.  However, at 1 hr, the entire hippocampus showed increased 
microgliosis.  By 6 hr, the hippocampal fimbria, rhinal cortices, thalamus, brainstem, and 
posterior striatum were similarly affected.  At 24 hr, the entire brain, including temporal, 
parietal, frontal, and occipital cortices showed microgliosis.  This continued through 72 
hr with a marked increase in the striatum.  By 168 hr (7 days), the effect began to wane 
and only areas very near the hippocampus showed gliosis (striatum, fimbria, rhinal 
cortices).  By 28 days, only the hippocampus was still experiencing microgliosis.  Note 
that the very bushy, round, and amorphous/ameboid microglia described here were only 
seen in the hippocampus.  Outside that region, microglia increased CR3 expression, but 
did not have marked changes in morphology.  Thus, although a widespread inflammatory 
response was mounted in response to LPS, the neurons survived. 
Here we report that both TLR4 and CD14 mRNA are induced following LPS 
injection.  TLR4 mRNA has been localized by others in mouse microglial cell cultures, 
but not in astrocytes, oligodendroglia, or neurons (Lehnardt et al., 2002, 2003).  In 
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contrast, in situ hybridization of rat brain demonstrated basal TLR4 and CD14 mRNA 
expression in the circumventricular organs, leptomeninges, and choroids plexi (Laflamme 
& Rivest, 2001).  Intrastriatal LPS injection similarly increased CD14 mRNA, but not 
TLR4 as detected by in situ hybridization (Nadeau & Rivest, 2002).  
Immunohistochemical analysis of TLR4 levels in the central nervous system (with or 
without LPS) has not been reported to our knowledge.  Singh and Jiang recently reported 
that peripheral administration of LPS did not cross the blood brain barrier, but rather 
bound endothelial cells which then signaled microglial to respond (Singh & Jiang, 2004).  
Although LPS clearly increased TLR4 RNA and immunostaining, the TLR4 
immunohistochemical analysis did not reveal a population of highly ramified, bushy, 
reactive microglia similar to those stained by CD45.  Possibly, the staining pattern we 
saw was endothelial cells, especially at the early time points.  Conversely, the TLR4 
staining pattern at 72 hr was reminiscent of the round and ameboid cells seen with CD45 
staining at 72 hr.  The ability of microglial to express TLR4 in response to LPS in vivo 
remains to be adequately demonstrated by dual label immunocytochemistry. 
In conclusion, we have examined the time course of the response of the brain to a 
single intrahippocampal injection of LPS.  The response had both a transient, acute phase 
as well as a chronic phase associated with the induced inflammation.  Evaluation of the 
phenotype of reactive microglia may lead to a better understanding of neuroinflammatory 
diseases. 
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Chapter 3 
Time-Dependent Reduction in Aβ Levels After Intracranial 
LPS Administration in APP Transgenic Mice 
Abstract 
Inflammation has been argued to play a primary role in the pathogenesis of 
Alzheimer’s disease.  Lipopolysaccharide (LPS) activates the innate immune system, 
triggering gliosis and inflammation when injected in the central nervous system. In 
studies described here, APP transgenic mice were injected intrahippocampally with 4 or 
10 µg of LPS and evaluated 1, 3, 7, 14, or 28 days later.  Aβ load was significantly 
reduced at 3, 7, and 14 days, but quickly returned near baseline 28 days after the 
injection.  No effects of LPS on Congophilic amyloid deposits could be detected.  LPS 
also activated both microglia and astrocytes in a time-dependent manner.  The GFAP 
astrocyte reaction and the Fcγ receptor microglial reaction peaked at 7 days after LPS 
injection, returning to baseline by 2 weeks post injection.  When stained for CD45, 
microglial activation was detected at all time points, although the morphology of these 
cells transitioned from an ameboid to a ramified and bushy appearance between 7 and 14 
days post injection.  These results indicate that activation of brain glia can rapidly and 
transiently clear diffuse Aβ deposits, but has no effect on compacted fibrillar amyloid.   
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Introduction 
Chronic neuroinflammation is a hallmark of many neurodegenerative diseases, 
including Alzheimer’s disease (AD, Akiyama et al., 2000).  The role of inflammation in 
AD is controversial, with two sides to the response.  Acute inflammation can be 
neuroprotective, aiding in removal of pathogens and protecting cells (reviewed in Streit, 
2002).  Conversely, excessive, chronic inflammation is thought to enhance cell death via 
an autotoxic mechanism (McGeer & McGeer, 2002).  Current transgenic animal models 
replicate the amyloid pathology, glial response, and cognitive impairment of AD, without 
apparent neurodegeneration.  One approach to more accurately reflect the conditions in 
AD brain is to inject lipopolysaccharide (LPS) into transgenic mice to enhance the 
inflammatory state of the brain.  It was hypothesized that LPS dosing might also alter 
amyloid deposition while triggering neurotoxicity.   
LPS is a Gram-negative bacterial cell surface proteoglycan, also known as 
bacterial endotoxin, which triggers an inflammatory response by the host.  LPS binds to 
circulating LPS binding protein, which subsequently transfers the LPS to the cell 
membrane bound cluster differentiation marker CD14, a common receptor for bacterial 
components (Heumann & Roger, 2002).  The CD14 protein does not contain an 
intracellular domain, so interaction with additional components is likely.  Toll like 
receptor 4 (TLR4), as well as myeloid differentiation protein MD2, form a complex 
through which LPS:CD14 can transduce a signal (Thomas et al., 2002).  Multiple 
cascades are involved in the signal transduction, with nuclear factor NFκB as a key 
player.  Downstream gene activation triggers the production of cytokines, nitric oxide, 
and prostanoids leading to the cellular inflammatory response. 
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LPS has been used to mimic the inflammatory conditions seen in human AD 
brain.  Acute and chronic application of LPS into the brain ventricles of rats resulted in 
gliosis, cytokine production, increased APP levels, cognitive deficits, and neurotoxicity 
limited to the forebrain cholinergic nuclei (Hauss-Wegrzyniak et al., 1998a,b, 2000, 
2002; Willard et al., 1999).  LPS has also been administered to amyloid-depositing 
transgenic mice to cause glial activation.  However, some investigators reported 
increased Aβ levels in response to LPS (Sly et al., 2001; Qaio et al., 2001; Sheng et al., 
2003), while others observed Aβ clearance (DiCarlo et al., 2001; Quinn et al., 2003).  
The experimental conditions of these previous reports vary, including the type and age of 
transgenic mice used; type, dose and route of administration of LPS; and post injection 
survival time.   
A potential mechanism of Aβ removal includes phagocytosis.  In vitro studies 
show that both microglia and astrocytes react to LPS with phagocytosis, as well as with 
production of potentially cytotoxic agents such as prostaglandins, cytokines, and reactive 
oxygen species (Kalmar et al., 2001).  Thus, this model of neuroinflammation may be 
useful in triggering the innate immune system to clear Aβ deposits, and/or kill neurons.  
The experiments described herein will address the overall hypothesis that neuroglia play 
a key role in the inflammation seen in AD, and may represent an innate mechanism of Aβ 
removal. In an effort to clarify the mechanism of Aβ clearance, dose-response and time-
dependence experiments were conducted using intrahippocampal injections of LPS into 
aged APP mice.  
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Materials and Methods 
Mouse Strains 
Transgenic mice were bred to develop Alzheimer’s like pathology using Tg2576 
APP mice as described previously (Holcomb et al., 1998).  APP mice and their 
nontransgenic littermates aged 16-17 months were used in this study.  Animals were 
group housed prior to surgery under a 12 hr light-dark cycle with free access to chow and 
water. 
Intrahippocampal Injections 
Mice were anesthetized using isoflurane and immobilized in a stereotaxic 
apparatus.  A single, one microliter injection of either saline, 4 µg/µl LPS, or 10 µg/µl 
LPS  (Salmonella abortus equi, Sigma, St. Louis, MO) was delivered over a two minute 
period into the right hippocampus (coordinates from bregma:  –2.7 mm posterior, -2. 5 
mm lateral, and -3.0 mm ventral).  The incision was closed with wound clips, isoflurane 
was discontinued, and the animal revived on a heated pad.  All mice completely 
recovered within five minutes.  Animals were singly housed for the post treatment 
survival period under standard vivarium conditions. We used at least four mice (4-7) for 
each condition, balanced for gender.  The dose response study had three conditions: APP 
mice injected with either saline, 4 µg LPS, or 10 µg LPS; all survived 7 days.  The time 
course utilized two genotypes for a total of 10 conditions.  Nontransgenics were injected 
with saline and survived 7 days, or were injected with 4 µg of LPS  and survived 1, 3, or 
7 days. APP mice were injected with saline and survived 7 days, or were injected with 4 
µg of LPS  and survived 1, 3, 7, 14, or 28 days. 
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Tissue Preparation 
Mice were anesthetized with pentobarbital, and then perfused transcardially with 
25 ml of normal saline, followed by 50 ml of freshly prepared neutral buffered 4% 
paraformaldehyde.  The brain was postfixed in 4% paraformaldehyde solution for 24 hr, 
then processed through a cryprotection schedule of 10, 20, then 30% sucrose.  Frozen 
brains were sectioned horizontally on a sliding microtome at 25 µm.  Sections were then 
stored in Dulbecco’s phosphate buffered saline pH 7.4 (DPBS) with 100 mM sodium 
azide at 4°C. 
Histology 
Immunohistochemical analysis was performed for each marker using six, 25 µm 
free-floating sections spaced 300 µm apart through the hippocampus.  Details of this 
procedure are described elsewhere (Gordon et al., 1997).  Briefly, sections were blocked 
for endogenous peroxidases (10% methanol and 3% hydrogen peroxide in 80% DPBS), 
washed with DPBS, then permeabilized (100 mM lysine, 0.2% triton x-100, 4% normal 
serum in DPBS).  Sections were then incubated overnight in the appropriate primary 
antibody (Table 5). The following day, sections were washed, and then incubated in 
appropriate biotinylated secondary antibody.  After another cycle of washes, the tissue 
was incubated with Vectastain® Elite® ABC kit (Vector Laboratories, Burlingame, CA).  
In the case of glial fibrillary acidic protein (GFAP), streptavidin-peroxidase was used 
rather than ABC.  The tissue was then washed and stained with a diaminobenzidine: 
peroxide system, followed by final washes.  In the case of CD45 and Fc gamma receptor 
II/III (FcγRII/III), nickel enhancement of the color development was used.  The extent of 
nonspecific binding was assessed in the absence of primary antibodies for all assays.  
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Sections were mounted onto slides, dehydrated, and cover slipped with DPX (E.M. 
Sciences, Fort Washington, PA).  Separately, compact plaques were evaluated after 
sections were slide mounted, by incubating in alkaline alcoholic saturated sodium 
chloride (AASSC), followed by 0.2% Congo red in AASSC.  Tissue damage was 
evaluated using a 0.05% cresyl violet (pH 3.3) solution. 
 
Table 5.  Primary Antibodies Used for Immunohistochemistry 
Antigen Type Source Catalog # Titer 
     
Aβ Rabbit polyclonal Biosource 44-136 1:10000 
CD45 Rat monoclonal Serotec MCA1031G 1:3000 
FcγRII/III  Rat monoclonal PharMingen 553141 1:3000 
GFAP Rat monoclonal Zymed 13-0300 1:3000 
 
Data Analysis 
Stained sections were imaged at 100x magnification, focusing on the molecular 
layer of CA1, CA3, and dentate gyrus (DG) regions of the injected hippocampus.  Images 
were then analyzed for area percent positive stain using Image-Pro® Plus software 
(MediaCybernetics, Silver Spring, MD).  Area percent stained was calculated for each 
individual region of the hippocampus, as well as an average of the three regions.  Results 
were averaged for each animal, and the treatment groups compared by one way analysis 
of variance (ANOVA) followed by post hoc analysis using Fisher’s protected least 
squares difference (PLSD, significance at p < .05).  Results shown are for the CA3 
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region, which showed the greatest effect.  Similar results were seen in all of the 
hippocampal regions analyzed, as well as for the average of the three.  
Results 
Dose Response 
Intrahippocampal injections of LPS were made into APP transgenic mice in order 
to optimize the Aβ reductions reported previously (DiCarlo et al., 2001).  Dose response 
studies were done using saline, 4, or 10 µg/µl of LPS. Animals were evaluated 7 days 
after the injection by immunohistochemistry for total Aβ burden using an anti-Aβ 
antibody which recognizes both Aβ1-40 and Aβ1-42.  Micrographs represent the injected 
hippocampus of a saline injected control (Fig. 13A) versus a 10 µg LPS-dosed APP 
mouse (Fig. 13B) are shown.  In the control mouse, both lightly stained, diffuse Aβ 
deposits and darkly stained, compacted deposits were seen.  LPS injection resulted in 
removal of a major portion of the diffuse deposits in the CA1 and CA3 regions of the 
hippocampus.  The quantification are from the CA3 region (the region indicated by the 
box in Fig. 13D).  Statistical analysis of the data shown in Figure 13C indicated a 
significant removal of Aβ in LPS-injected APP mice (F(2,13) = 6.6, p < .05).   
The effect of LPS injection on compact amyloid plaque burden in APP mice was 
determined with Congo red staining.  Compact plaques were detected typically near the 
hippocampal fissure in the saline injected mice (Fig. 13D).  No detectable changes in the 
amyloid load were seen with LPS treatment in any hippocampal subfield (Fig. 13E).  
Quantitation also failed to reveal a significant change in amyloid burden in CA3  
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(Fig. 13F), CA1, or dentate gyrus subfields, or in the average of all fields from the 
hippocampus.  Similarly, LPS treatment was not accompanied by reductions in amyloid 
detected by thioflavin-S (results not shown).  
 
 
 
Figure 13.  Dose response of LPS stimulated Aβ removal.  APP mice were injected with 
saline (A,D) or 10 µg of  LPS (B,E) 7 days prior to sacrifice.  Immunostaining for total 
Aβ burden is shown in panels A and B.  A significant reduction at both dosages is shown 
in panel C. Histochemical staining of compact plaques with Congo red dye is shown in 
panels D and E.  No reduction was detected as a result of LPS dosing (F). The CA3 
subregion enclosed by a box in Panel D represents the area used for calculating percent 
positive stain in data analyses (C,F).  Abbreviations: CA1, CA3: subregions of Ammon’s 
horn; DG: dentate gyrus. Scale bar = 250 µm.  * p < .05. 
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Gliosis, a possible link to the mechanism of Aβ reduction in APP mice, was 
analyzed using CD45 staining for reactive microglia.  Saline- injected APP mice 
(controls) are shown in Figure 14A.  These mice have CD45+ microglia largely restricted 
to the vicinity of putative amyloid plaques and the injection site within the hilus of the 
dentate gyrus.  We use the term “putative” amyloid plaques because, even though such 
aggregates of microglia have previously been demonstrated to surround Congophilic 
cores (Gordon et al.; 2002), no Congo red counterstain was performed on these sections.  
LPS treatment of APP mice caused a widespread eruption in the number and staining 
intensity of CD45+ microglia throughout the hippocampus (Fig. 14B).  Both doses 
caused significant increases in CD45 immunoreactivity (mean area % for saline dose = 
1.1 ± 0.3; 4 µg dose = 12.3 ± 4.0; 10 µg dose = 9.1 ± 2.6).  The 10 µg dose caused 
increased reactivity to extend outside the injected hippocampus, spreading into the 
adjacent cortices and even to the contralateral hippocampus (data not shown). 
Astrogliosis was detected using the astrocyte specific marker GFAP.  Saline-
injected APP mice had diffuse distribution of GFAP+ astroglial cells, as well as plaque–
associated clusters of astroglia (Fig. 14C).  LPS treatment caused an increase in the 
staining intensity of GFAP staining throughout the hippocampus (Fig. 14D).  Both doses 
caused a mild, but not significant, increase in GFAP immunoreactivity, (mean area % for 
saline dose = 17.1 ± 4.2; 4 µg dose = 19.7 ± 3.9; 10 µg dose = 18.6 ± 3.1).  The highest 
dose triggered a notable glial response outside the injected area (data not shown). 
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Figure 14.  Glial response to LPS.  APP mice injected with saline or with 10 µg of LPS, 
7 days prior to sacrifice, showed increased microglial activity due to LPS (B) versus 
saline (A).  GFAP immunoreactivity showed increased astrocyte activity in LPS- injected 
(D) versus saline- injected (C) APP mice.  Scale bar = 250 µm. 
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The potential for LPS injection to cause tissue damage was examined 
histochemically with cresyl violet stain.  Sections were evaluated for evidence of 
neurodegeneration, which included pyknotic nuclei as well as gross cell loss in the 
pyramidal and granule cell layers of the hippocampus.  Some animals had evidence of 
mechanical trauma in the injection vicinity, but this was observed in both saline- and 
LPS-injected mice to the same degree.  No widespread evidence of neuronal damage 
caused by LPS was detected.   
Overall, the dose response study demonstrated that LPS injection into the 
hippocampus of APP mice led to clearance of Aβ within one week, without altering 
compact plaque load or triggering neurodegeneration.  Concurrently, treatment enhanced 
gliosis, suggesting a glial-mediated mechanism of Aβ reduction.  The 4 µg LPS dose was 
chosen for use in subsequent experiments as adequate clearance of Aβ was seen at that 
dose. 
Time Course 
To further evaluate the LPS-induced clearance of Aβ, a time course was 
conducted.  APP mice were injected with 4 µg of LPS, and allowed to survive 1, 3, 7, 14, 
or 28 days.  Nontransgenic mice were also injected with LPS, and survived 1, 3, or 7 days 
post injection. Control groups for both genotypes received saline injections, with 7 day 
survival periods.  Aβ burden in APP mice was determined immunohistochemically using 
an anti-Aβ antibody, and analyzed in the CA1, CA3, and DG subfields of the 
hippocampus.  Analysis of variance showed a time-dependent effect on Aβ levels in LPS-
injected mice (F(5,30) = 2.7, p < .05), particularly in the CA3 subregion (Fig. 15).  Post hoc 
analysis using Fisher’s PLSD indicated a statistically significant removal of Aβ in LPS 
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injected APP mice from 3-14 days, which returned to baseline by 28 days.  As in the dose 
response study at 7 days, no effect of LPS injection on Congo red stained plaques in APP 
mice was seen in any subregion of the hippocampus, or in the hippocampus overall, at 
any time point (data not shown).  
 
 
 
Figure 15.  Time dependent removal of Aβ by LPS injections.  APP mice were injected 
with saline or 4 µg of LPS and immunostained for Aβ.  Mice injected with LPS were 
killed at 1, 3, 7, 14, or 28 days post injection.  Control mice were injected with saline and 
killed 7 days later.  Results are mean ± SEM of percent area stained in the CA3 region of 
the hippocampus, indicating significant reductions in diffuse Aβ from 3-14 days.   
X-axis label C = saline injected control mice killed 7 days post injection; * p < .05. 
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Gliosis, a possible link to the mechanism of Aβ reduction in APP mice, was 
analyzed by looking at reactive glial markers.  Representative micrographs from the CA3 
subregion of the hippocampus of APP mice are presented in Figure 16.  Reactive 
microglia were immunohistochemically analyzed for CD45 expression in both APP and 
nontransgenic mice.  Saline-injected APP mice demonstrated intense reactivity in 
conjunction with putative amyloid deposits (Fig. 16A).  LPS treatment resulted in a 
widespread activation of microglia (Fig. 16B).  LPS similarly activated microglia in 
nontransgenics (not shown).  As shown in Panel C, the increase in CD45 immunostaining 
was time dependent (F(9,48) =  8.6, p < .0001).  Post hoc analysis indicated a statistically 
significant increase beginning at 3 days, peaking at 7 days, and remaining somewhat 
elevated throughout the time course to 28 days. Notably, the APP mice were significantly 
more reactive than their nontransgenic littermates at 7 days with CD45 immunostaining 
(p < .01).   
Astrocytes in both APP and nontransgenic mice were detected using the astrocyte 
specific marker GFAP, as shown for the CA3 subregion in Figure 16.  The hippocampus 
of saline-injected mice showed many GFAP+ astrocytes (APP mouse shown in Fig.16D).  
LPS treatment resulted in a widespread activation of astrocytes (Fig. 16E).  The increase 
in GFAP immunostaining was time dependent (F(9,48) = 3.7, p < 0.005), shown in Panel F.  
Post hoc analysis showed GFAP expression peaking at 7 days, then returning to control 
levels by 14 days.  This is in contrast to CD45 which remained elevated through the 28 
day time point. LPS injection into nontransgenic mice resulted in a mild increase in 
GFAP immunoreactivity compared to saline injection, which was not statistically 
significant.   
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FcγRII/III immunostaining of microglia was investigated following LPS injection.  
Figure 16G-H shows the CA3 subregion analysis of APP mice.  Saline-injected mice 
showed no notable immunoreactivity.  LPS treatment led to a widespread reaction in the 
injected hippocampus of APP mice (Fig. 16H).  The increase in immunostaining was 
time dependent (F(9,48) = 1.8, p < .05), shown in Figure 16I.  Post hoc analysis indicated 
significant elevation of FcγRII/III at 3 and 7 days post injection in APP mice.  Levels 
returned to baseline by 14 days. Nontransgenic mice showed elevated reactivity as well, 
which was significant at 3 days when the data were analyzed separately from the 
transgenics.     
 
Figure 16.  Time dependent glial reaction to LPS injection.  APP mice were injected with 
saline (A,D,G) or 4 µg of LPS (B,E,H).   Micrographs are representative of a 7 day 
survival for both groups, imaging the CA3 region of the injected hippocampus.  
Immunostaining for CD45 (A,B) showed intense microglial reaction to LPS, which was 
significant from 3-28 days post injection (C). Immunostaining for GFAP (D,E) showed 
reactive astrocytes responding to LPS, which was significant at 7 days post injection (F).  
Immunostaining for FcγRII/III (G,H) showed upregulation of this receptor in response to 
LPS, which was significant from 3-7 days (I).  Scale bar = 50 µm; x-axis label C = saline 
injected control mice; NT = nontransgenic; * p < .05 versus control for that genotype;  
** p < .05 versus APP controls as well as compared to NT at the same time point. 
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Figure 16.  Time dependent glial reaction to LPS injection. 
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The morphology of the microglia across time was examined with CD45 
immunostaining (Fig. 17).  Saline-injected APP mice showed predominantly lightly 
stained, resting, ramified microglia with thin delicate processes (Fig. 17A).  Treatment 
with LPS resulted in a production of rounded, ameboid microglia, staining intensely with 
CD45, appearing 1-7 days post injection (Fig. 17B).  Starting at 7 days and lasting though 
28 days, microglia acquired a hyper-ramified, bushy appearance, with short thick 
processes stained heavily with CD45 (Fig. 17C).  CD45-positive microglia, associated 
with putative amyloid deposits in saline-treated APP mice, have a bushy appearance and 
are heavily stained by CD45 antibodies (Fig. 17D). After LPS injection, ameboid 
microglia surrounded these putative plaques at 1, 3, and 7 days (Fig. 17E).  The microglia 
resumed their bushy appearance at 7, 14, and 28 days, and remained widely distributed 
throughout the hippocampus as well as associated with putative amyloid plaques (Fig. 
17F). Particularly at the 7 day time point, there was overlap with multiple 
morphologically different microglia being detected. 
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Figure 17.  Altered microglial morphology in response to LPS.  CD45 immunostaining 
was examined at each time point. Micrographs are from the CA1 molecular layer of APP 
mice injected with saline 7 days earlier (panels A,D), LPS 3 days earlier (panels B,E) or 
LPS 28 days earlier (panels C,F).  Micrographs were chosen from a region free of 
putative amyloid plaques (A-C) or a field centered on a putative amyloid plaque (D-F). 
Scale bar = 50 µm.  
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Discussion 
These findings provide evidence of an innate mechanism of diffuse Aβ removal 
present in APP transgenic mice.  LPS injections into the hippocampus led to a time-
dependent clearance of parenchymal Aβ.  These results confirm those reported earlier by 
our lab and others (Dicarlo et al., 2001; Quinn et al., 2003).  Congophilic plaque load was 
unaffected, suggesting these different pools of amyloid are selectively accessible by glial 
cells or other clearance mechanisms.  Potential mechanisms for removal of diffuse Aβ 
include phagocytosis by glial cells, secretion of degradative enzymes, or facilitation of 
Aβ clearance from the brain by mechanisms other than phagocytosis.  Scavenger 
receptors may represent the link between LPS and Aβ, as these receptors have been 
shown to bind both ligands, and can mediate Aβ phagocytosis in vitro (Husemann et al., 
2002).   Though both microglia and astroglia have phagocytic capabilities in vitro, the 
time course of Aβ reduction observed in these experiments most closely mirrors that of 
microglial activation.  Furthermore, early time points were associated with a shift in 
microglial morphology to an ameboid shape that is associated with phagocytic capability 
in other systems.   
Another marker for a phagocytic state of microglia is Fcγ receptor expression.   
FcγRII/III were up-regulated on microglial cells in response to LPS from 3-7 days post 
injection.   Previous studies performed by our laboratory have demonstrated that anti-Aβ 
antibodies injected into the brain of APP mice stimulated microglia to remove Aβ in a 
process that appears at least partially Fc receptor mediated (Wilcock et al., 2003, 
2004a,b).  The endogenous ligand for Fcγ receptor is the Fc region of IgG.  However, 
there is no evidence in the current studies that anti-LPS or anti-Aβ antibodies have been 
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produced in the LPS-injected mice, although such a possibility cannot be ruled out.  On 
the other hand, it has been demonstrated that LPS can induce Fcγ expression in the 
absence of IgG, possibly as part of cell activation.  In addition, Fc receptor expression by 
macrophages can be regulated by cytokines as well as by LPS (Amigorena et al., 1989; 
Lynch et al., 1990; Laszlo and Dickler, 1990; Loughlin et al., 1992; Keller et al., 1994).  
Thus, it is possible that the induction of FcγRII/III reflects another facet of microglial 
activation and not the specific presence of immunoglobulin. 
The microglial response, though decreasing with time, remained significantly 
activated throughout the time course.  At 28 days post injection, CD45+ microglia were 
still significantly activated, and had adopted a hyper-ramified, bushy appearance.  The 
glia were both plaque-associated as well as widespread throughout the injected 
hippocampus.  It was interesting that the appearance of microglia at 28 days was very 
similar to those associated with plaques in our control, saline treated APP animals.  Our 
experiments also demonstrated exacerbated gliosis after 7 days in the LPS dosed APP 
transgenics compared to their nontransgenic littermates.  Both CD45+ microglia and 
GFAP+ astrocytes were more intensely immunolabeled in the transgenics.  These results 
suggest a role for Aβ in the inflammatory response.   
An intriguing observation occurred at the 28 day time point.  Aβ levels, which 
had been significantly reduced from 3-14 days post injection accumulated rapidly 
between 2 and 4 weeks after LPS administration, and returned to pre-injection levels after 
one month.  The original Aβ burden in these mice developed over their lifespan of 16-17 
months.  This finding is highly significant because it suggests that amyloid pools are 
more labile than previously assumed.  It is unclear whether this rapid re-accumulation 
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resulted from cessation of Aβ removal mechanisms, enhancement of Aβ deposition or 
both.  If the LPS molecule is required for sufficient microglial activation and Aβ 
removal, complete clearance of LPS might signal cessation of removal mechanisms as 
the immune response is no longer stimulated.  On the other hand, evidence of enhanced 
APP processing in response to insult is well documented.  Chronic neuroinflammation 
and trauma-induced injury models both showed increases in APP and its processing 
(Siman et al., 1989; Kawarabayashi et al., 1991; Griffin et al., 1994; Banati et al., 1995; 
Hauss-Wegrzyniak et al., 1998; Sugaya et al., 1998).  Kainate lesions also increased APP 
expression in astrocytes (Siman et al., 1989; Wright et al., 1999).  Enhanced alpha- 
secretase as well as presenilin activity were shown in other injury models (Brugg et al., 
1995; Pennypacker et al., 1999).  Future experiments will examine expression and 
proteolytic processing of APP after LPS administration to ascertain whether they play a 
role in this rapid re-accumulation of AB burden.  
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Chapter 4 
Dexamethasone Suppresses LPS-Induced Microglial Activation 
and Amyloid Clearance in APP Transgenic Mice 
Abstract 
Inflammation has been argued to play a primary role in the pathogenesis of 
Alzheimer’s disease (AD).  Mice transgenic for mutant human amyloid precursor protein 
(APP) have amyloid deposits, gliosis, and cognitive impairment, without apparent 
neurodegeneration.  Previous efforts by our group to use lipopolysaccharide (LPS) to 
elicit neurodegeneration in APP mice were unsuccessful.  Instead we saw a surprising 
reduction in Aβ burden concurrent with the inflammatory response.  In studies described 
here, we clarify the mechanisms involved in LPS mediated removal of Aβ, using 
dexamethasone to inhibit the microglia response.  APP mice were intrahippocampally 
injected with LPS and survived 3 or 7 days with or without dexamethasone co-treatment.  
Brain tissue was then analyzed by immunohistochemistry and quantitative real time PCR.  
Total Aβ burden was reduced 7 days after LPS injection; this was prevented by co-
treatment with dexamethasone.  Markers of general microglial activation, CD45 and 
complement receptor 3, were increased by LPS and inhibited by dexamethasone.  In 
contrast, the Fcγ receptors II/III and scavenger receptor A were increased by LPS but 
unaffected by dexamethasone treatment.  The implications of the glial response to LPS 
and dexamethasone are two-fold.  First, cells do not require general activation in order to 
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upregulate their expression of receptors capable of mediating phagocytosis.  However, in 
order to effectively clear out foreign or toxic materials (such as LPS, Aβ, etc.) general 
cell activation is necessary.   
Introduction 
Alzheimer’s disease (AD) is one of many neurodegenerative disorders marked by 
chronic inflammation (Akiyama et al., 2000).  Although amyloid plaques in human AD 
brain are surrounded by reactive astrocytes and microglia, the cellular response is not 
well understood (Itagaki et al.,1989 ).  Acute inflammation can be neuroprotective, aiding 
in removal of pathogens and protecting cells (Streit, 2002).  Conversely, excessive, 
chronic inflammation is thought to cause neuron death via an autotoxic mechanism 
(McGeer & McGeer, 2002).  Current transgenic mouse models replicate the amyloid 
pathology, glial response, and cognitive impairment of AD, without apparent 
neurodegeneration (Gordon et al., 2001, 2002).  
Based on the inflammation hypothesis of AD, we have created a model using LPS 
intracranial injections into mice carrying a mutant human amyloid precursor protein 
(APP) transgene. LPS is expressed on the cell wall of Gram-negative bacteria, and can 
cause an inflammatory response by the host (Palsson-McDermott & O’Neil, 2004).  Once 
in the host, LPS binds to circulating LPS binding protein, which subsequently transfers 
the LPS to cell membrane bound cluster differentiation marker CD14 (Heumann & 
Roger, 2002).  Toll like receptor 4 (TLR4), as well as myeloid differentiation protein 
MD2, form a complex through which LPS:CD14 can transduce a signal (Thomas et al., 
2002).   
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We have reported previously that direct injection of lipopolysaccharide (LPS) into 
the hippocampus of APP mice resulted in reductions in Aβ burden (DiCarlo et al., 2001; 
Herber et al., 2004b).  Similar findings were seen after intraperitoneal injections of LPS 
(Quinn et al., 2003) although systemic administration to young mice may have the 
opposite effect and precipitate amyloid deposits where none previously existed (Qiao et 
al., 2001).  A potential mechanism of Aβ removal includes phagocytosis (D'Andrea et al., 
2004).  In vitro studies showed that both microglia and astrocytes respond to LPS with 
phagocytosis, as well as with production of potentially cytotoxic agents such as cytokines 
and reactive oxygen species (Kalmar et al., 2001; Shaffer et al., 1995).   Wyss-Coray and 
colleagues also showed reductions in amyloid deposits when brain slices from APP mice 
were coated with astrocytes (2003).   
Here we describe experiments that explore the glial contribution to the LPS 
associated Aβ reductions.  Intrahippocampal LPS injections reduced Aβ burden and 
stimulated microgliosis.  The microglia response was then inhibited with dexamethasone, 
resulting in Aβ burdens at control levels.   
Materials and Methods 
Mouse Strains 
Transgenic mice were bred to develop Alzheimer’s like pathology using Tg2576 
APP mice as described previously (Holcomb et al., 1998).  APP mice and their 
nontransgenic littermates aged 17 months were used in this study.  Animals were group-
housed prior to surgery under a 12 hr light-dark cycle with free access to chow and water. 
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Intrahippocampal Injections 
Mice were anesthetized using isoflurane and immobilized in a stereotaxic 
apparatus.  A single, one microliter injection of either saline or 4 µg/µl of LPS 
(Salmonella abortus equi, Sigma, St. Louis, MO) was delivered over a two minute period 
into the hippocampus (coordinates from bregma:  –2.7 mm posterior, +/-2. 5 mm lateral, 
and -3.0 mm ventral).  The incision was closed with wound clips, isoflurane was 
discontinued, and the animal was revived under ambient conditions.  All mice completely 
recovered within five minutes.  Animals were singly housed for the post treatment 
survival period under standard vivarium conditions. We used at least 5 mice (5-10) for 
each genotype and treatment, balanced for gender.  Post LPS injection, the survival 
period was either 3 or 7 days. 
Drug Administration 
Two different time points were evaluated.  A 3 day study was conducted after 
intrahippocampal LPS injection.  Within one hour of injection, mice were administered 
dexamethasone (5 mg/kg, ip), followed by twice daily administration for a total of 3 days.  
A 7 day study was conducted by pre-treating with dexamethasone for 24 hours, injecting 
with LPS, then continuing twice daily dexamethasone for 7 days.  
Tissue Preparation 
Mice were overdosed with pentobarbital, and then perfused transcardially with 25 
ml of normal saline.  Tissue was collected for RNA analysis by removing the 
hippocampus and storing at -80°C.  For immunohistochemistry, the brain was post fixed 
in 4% paraformaldehyde solution for 24 hours, then processed through a cryprotection 
schedule of 10, 20, and 30% sucrose.  Brains were sectioned horizontally at 25 µm on a 
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freezing stage using a sliding microtome.  Sections were then stored in Dulbecco’s 
phosphate buffered saline pH 7.4 (DPBS) with 100 mM sodium azide at 4°C. 
Histology 
Immunohistochemical analysis was performed for each marker using six, 25 µm 
free-floating sections spaced 200 µm apart through the hippocampus.  Details of this 
procedure are described elsewhere (Gordon et al., 1997).  Briefly, sections were blocked 
for endogenous peroxidases (10% methanol and 3% hydrogen peroxide in 80% DPBS), 
washed with DPBS, and then permeabilized (100 mM lysine, 0.2% triton x-100, 4% 
normal serum in DPBS).  Sections were then incubated overnight in the appropriate 
primary antibody (Table 6). The following day, sections were washed, and then incubated 
in appropriate biotinylated secondary antibody.  After another cycle of washes, the tissue 
was incubated with Vectastain® Elite® ABC kit (Vector Laboratories, Burlingame, CA).  
The tissue was then washed and stained with a nickel: diaminobenzidine: peroxide 
system, followed by final washes.  In the case of Aβ immunostaining, nickel 
enhancement of the color development was not used.  The extent of nonspecific binding 
was assessed in the absence of primary antibodies for all assays.  Sections were mounted 
onto slides, dehydrated, and cover-slipped with DPX (E.M. Sciences, Fort Washington, 
PA).   
Slide-mounted untreated sections were stained with Congo red to detect compact 
amyloid plaques.  Slides were briefly hydrated in water, and then incubated in alkaline 
alcoholic saturated sodium chloride (AASSC) for 20 minutes, followed by 30 minutes in 
0.2% Congo red in AASSC.  Slides were then quickly dehydrated through a graded 
ethanol series, cleared in xylene, and cover-slipped.   
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Table 6.  Primary Antibodies Used for Immunohistochemistry  
Antigen Antibody Type Source Catalog # Titer 
 
Aβ 
 
Rabbit polyclonal 
 
Kind gift from 
Dr. Paul 
Gottschall 
 
 
N/A 
 
1:10000
CD45 
 
Rat monoclonal 
 
Serotec MCA1031G 1:10000
CR3 
 
Rat monoclonal 
 
Serotec MCA711 1:3000 
FcγRII/III 
 
Rat monoclonal 
 
PharMingen 553141 1:3000 
SRA 
 
Rat monoclonal 
 
Serotec MCA1322 1:3000 
 
Immunostained sections were imaged at 100x magnification, focusing on the 
CA1, CA3, dentate gyrus, and hippocampal fissure subregions of the hippocampus, as 
well as the anterior cortex.  Images were then analyzed for area percent positive stain 
using Image-Pro® Plus software (MediaCybernetics, Silver Spring, MD).  Area percent 
stained was calculated for each individual region of the hippocampus, and averaged to 
calculate the staining for the entire hippocampus.  Results were averaged for all sections 
from each animal, and the treatment groups compared by one way analysis of variance 
(ANOVA) followed by post hoc analysis using Fisher’s protected least squares difference 
(PLSD, significance at p < .05).  In some cases, results are reported in terms of fold 
change from control levels.  In other instances, the ratio of staining in the hippocampus to 
that found in the anterior cortex was used to normalize for the variable amyloid 
deposition in individual mice. 
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RNA Analysis 
Tissue from the hippocampus was analyzed for mRNA expression by reverse 
transcription followed by quantitative real time polymerase chain reaction (qRT-PCR), as 
previously described (Dickey et al., 2003).  RNA was extracted from the injected 
hippocampus using Qiagen’s Rneasy® procedure (Valencia, CA).  The purified RNA 
was then assayed using Molecular Probes RiboGreen® RNA quantitation kit (Molecular 
Probes, Eugene, OR).  Each sample was then diluted in water to a final concentration of 
50 ng/µl or 5 ng/µl.  The 50 ng/µl samples were run on a 1% agarose gel using ethidium 
bromide/ultraviolet detection to verify RNA integrity.  
A composite of all RNA samples was made in order to prepare a standard curve 
ranging from 0.2 – 50 ng/µl.  Reverse transcription with mMLV (Invitrogen, Carlsbad, 
CA) was then performed on the standard dilutions and 5 ng of each sample RNA 
solution.  The resulting cDNA was then subjected to qRT-PCR using SYBR® Green 
PCR Master Mix (Molecular Probes, Eugene, OR).  Table 7 contains the primer 
sequences used in the qRT-PCR reaction.  For each mRNA of interest, a melt curve 
analysis of the qRT-PCR product was performed after cycling was complete.  
Fluorescence was read in 1°C increments from 56-99°C. Primer pairs were designed to 
yield a single, specific product, with no evidence of primer-dimer formation. 
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Table 7.  Primer Sequences for RNA Analysis  
Transcript Primer Pairs 
 
18S rRNA 
 
F: 5’-GTAACCCGTTGAACCCCATT-3’ 
R: 5’-CCATCCAATCGGTAGTAGCG-3’ 
 
CD45 
 
 
F: 5’-CAGAGCATTCCACGGGTATT-3’ 
R: 5’-GGACCCTGCATCTCCATTTA-3’ 
 
IL1β F: 5’-CTCATTGTGGCTGTGGAGAA-3’ 
R: 5’-GCTGTCTAATGGGAACGTCA-3’ 
 
FcγRIIb 
 
F: 5’-GGAAGAAGCTGCCAAAACTG-3’ 
R: 5’-CCAATGCCAAGGGAGACTAA-3’ 
 
SRA F: 5’-GACGCTTCCAGAATTTCAGC-3’ 
R: 5’-ATGTCCTCCTGTTGCTTTGC-3’ 
 
 
For each mRNA of interest, the threshold cycle [C(T)] values from the qRT-PCR 
were determined.  To create a linear curve, the log of the ng of RNA in each standard was 
plotted against the average C(T) value (each sample and standard was analyzed in 
triplicate).  Next, the log of the ng of RNA in each sample were calculated, and then 
converted to ng of RNA.  For a given reverse transcription, all targets of interest were 
normalized to results for 18S ribosomal RNA (18S rRNA) for the same sample to control 
for variations in the starting RNA concentration and reaction efficiency.  The ratio of the 
ng of target RNA to ng of 18S rRNA was calculated, and the results subjected to one way 
ANOVA, followed by Fisher’s PLSD with significance taken at p < .05.  The final results 
are presented as fold change versus saline injected control mice. 
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Results 
Intrahippocampal injections of LPS were made into APP transgenic mice and the 
subsequent neuroinflammatory effects on amyloid load evaluated.  We first looked at 
brain amyloid burden, considering both total Aβ and Congophilic amyloid deposits.  
Figure 18A-D shows the changes in total Aβ burden after treatment.  The micrographs 
are representative of the injected hippocampus of mice which survived 7 days.  Control 
mice showed substantial amounts of Aβ immunostaining, including focal aggregations 
scattered throughout the molecular layer of the CA subfields as well as laminar 
accumulations along the hippocampal fissure and outer molecular layer of the dentate 
gyrus (Fig. 18A).  In contrast, LPS treated mice showed less Aβ staining throughout the 
hippocampus (Fig. 18B). Reductions in the laminar accumulations were particularly 
striking.  Mice both injected with LPS and co-treated with dexamethasone showed many 
deposits and laminar accumulation (Fig. 18C), similar to control mice. The area percent 
positive stain was calculated for each region of the hippocampus, with the greatest effects 
seen at the hippocampal fissure.  The average area percent of the entire hippocampus was 
compared to the amount of Aβ staining in the ipsilateral anterior cortex to control for 
inter-animal variability.  The mean area percent ± standard error of the mean for the 
anterior cortex was not significantly different among the groups:  18.5  ± 3.6 saline, 18.8 
± 2.9 LPS, 14.8 ± 1.3 LPS-dexamethasone at 3 days; 12.5 ± 2.9 saline, 19.4 ± 2.2 LPS, 
15.4 ± 2.2 LPS-dexamethasone at 7 days.  Statistical analysis revealed that the LPS 
treated group surviving 7 days had significant reductions in Aβ load in the hippocampus 
compared to saline injected control mice.  This effect was completely blocked by 
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concurrent administration of dexamethasone.  No changes in Aβ load were found at 3 
days in any of the groups (Fig. 18D). 
The effect of LPS injection on compact plaques was evaluated using Congo red 
staining, shown in Figure 18E-H.  The micrographs are representative of the injected 
hippocampus of mice which survived 7 days.  Saline injected mice showed several focal 
deposits along the hippocampal fissure (Fig. 18E).  LPS treated mice showed similar 
numbers and sizes of deposits in the hippocampus in the absence (Fig. 18F) and presence 
(Fig. 18G) of dexamethasone at both 3 and 7 days.  These results were analyzed in the 
same manner as for Aβ immunostaining and are presented in Figure 18H. There were no 
statistically significant effects of LPS or dexamethasone on Congo red levels at either 
time point.   
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Figure 18.  LPS injection reduced diffuse but not compact amyloid deposits and was 
reversed by dexamethasone.  APP mice were injected with saline, LPS, or LPS plus 
concurrent dexamethasone treatment for 3 or 7 days.  Micrographs are representative of 
animals survived 7 days.  Immunostaining for Aβ in saline injected mice showed many 
deposits throughout the hippocampus (A).  LPS injection reduced the total amount of Aβ 
staining in the hippocampus (B).  LPS injection plus dexamethasone co-treatment 
resulted in many Aβ deposits (C), similar to saline injected mice.  The LPS-induced 
reduction in Aβ was significant at the 7 day time point and blocked by dexamethasone 
(D).  In contrast, similar amounts of Congophilic deposits were seen in saline injected 
(E), LPS injected (F), and LPS plus dexamethasone co-treated groups (G).  There was no 
significant difference in Congo red staining between any of the treatment groups.  Scale 
bar = 500 µm, * p < .05.
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Figure 18.  LPS injection reduced diffuse but not compact amyloid deposits and was 
reversed by dexamethasone. 
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Two markers of general microglial activation, CD45 and CR3 were analyzed by 
immunohistochemistry and are shown in Figure 19.  All micrographs are from the 
injected hippocampus of mice which survived 7 days.  CD45 (Fig. 19A) and CR3 (Fig. 
19E) stained reactive microglia in association with putative amyloid deposits in saline 
injected mice.  LPS injection resulted in a widespread activation of both CD45-positive 
(Fig. 19B) and CR3-positive (Fig. 19F) microglia, throughout the hippocampus and 
nearby cortices.  The insets in these panels show higher power micrographs of the 
microglial morphology.  Dexamethasone treatment of LPS -injected mice blocked the 
elevation of CD45 (Fig. 19C) and CR3 (Fig. 19G) staining, similar to that observed in 
saline injected mice.  Quantitation of the fold change of the area percent stained in the 
dentate gyrus compared to saline injected control mice is shown in Figure 19D for CD45 
and Figure 19H for CR3.  Similar effects were seen on all regions of the hippocampus, 
but the injection site was typically in the hilus of the dentate gyrus.  Two way ANOVA 
for CD45 revealed significant effects of treatment (F2,46 = 39, p < .0001), time (F1,46 = 
5.8, p = .02), and interaction (F2,46 = 14, p < .0001). Similar results for CR3 showed 
significant effects of treatment (F2,46 = 17, p < .0001), time (F1,46 = 76, p < .0001),  and 
interaction (F2,46 = 3.5, p = .04). Post hoc analysis confirmed that both the CD45 and 
CR3 responses were significantly elevated at 3 days and peaked at 7 days after LPS 
injection.  Dexamethasone inhibited this reaction at both time points; levels were no 
different from controls. 
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Figure 19.  CD45 and CR3 are induced by LPS and inhibited by co-treatment with 
dexamethasone.  APP mice were injected with saline, LPS, or LPS with concurrent 
dexamethasone treatment for 3 or 7 days.  Micrographs are representative of animals 
survived 7 days.  Saline injected animals showed detectable levels of CD45 (A) and CR3 
(E).  Both CD45 (B) and CR3 (F) showed widespread increases after LPS injection; the 
insets depict higher magnification of reactive microglia.  CD45 and CR3 also showed an 
effect of time; both were significantly elevated at 7 days compared to 3 days after LPS 
injection.  Dexamethasone co-treatment inhibited CD45 (C) and CR3 (G) at both time 
points.  Quantitation of the fold change versus saline injected controls is presented in 
Panel D (CD45) and Panel H (CR3).  Scale bar = 500 µm, * p < .05 compared to saline 
injected controls,  # p < .05 compared to the 3 day time point.   
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Figure 19. CD45 and CR3 are induced by LPS and inhibited by co-treatment with 
dexamethasone.   
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Two markers of the phagocytic capabilities of microglia, the low affinity Fc 
gamma receptors FcγRII/III and scavenger receptor SRA, were also examined by 
immunohistochemistry and are shown in Figure 20.  All micrographs are from the 
injected hippocampus of mice which survived 7 days.  FcγRII/III staining was associated 
with putative amyloid deposits, particularly along the hippocampal fissure in saline 
injected mice (Fig. 20A).  LPS injection resulted in a marked response throughout the 
hippocampus (Fig. 20B).  Dexamethasone treatment of LPS injected mice had no effect, 
and many FcγRII/III-positive microglia were seen (Fig. 20C), similar to mice who had 
received LPS injection only.  The insets in Figure 20C and G show higher power 
micrographs of the microglia. Quantitation of the fold change of the area percent stained 
in the dentate gyrus compared to saline injected control mice is reported.  FcγRII/III 
staining in LPS injected and LPS-dexamethasone co-treated mice after 3 and 7 days were 
significantly elevated compared to controls when analyzed by ANOVA (Fig. 20D: F(2,46) 
= 7.8, p = .001).  There was no significant effect of time, with similar increases at both 3 
and 7 days.  SRA immunostaining results were similar to FcγRII/III.  Saline injected mice 
showed little SRA immunoreactivity (Fig. 20E).  LPS injection resulted in a widespread 
reaction throughout the hippocampus (Fig. 20F).  Dexamethasone treatment of LPS 
injected mice had no effect, and many SRA-positive microglia were seen (Fig. 20G), 
similar to mice who had received LPS injection only.   Statistical analysis of SRA 
staining using ANOVA revealed a significant effect of LPS treatment (Fig. 20H: F(2,46) = 
4.0, p = .03).  Note that because immunostaining in the control condition was very low, 
fold inductions for this marker are extremely large, and highly variable.  SRA levels in 
LPS- injected and LPS plus dexamethasone co-treated mice were increased by 200 fold 
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after 3 days, and 100 fold after 7 days.  An insignificant effect of time was noted, with 
similar inductions of SRA at 3 and 7 days. 
 
Figure 20.  FcγRII/III and SRA are induced by LPS but not inhibited by co-treatment with 
dexamethasone.  APP mice were injected with saline, LPS, or LPS with concurrent 
dexamethasone treatment for 3 or 7 days.  Micrographs are representative of animals 
survived 7 days.  Low levels of FcγRII/III were seen in saline injected mice (A).  No 
SRA staining is evident after saline injection (E).  Both FcγRII/III (B) and SRA (F) 
showed widespread increases after LPS injection.  Only a mild, insignificant effect of 
time was noted.  Dexamethasone co-treatment did not inhibit FcγRII/III (C) or SRA (G) 
levels at either time point; the insets depict higher magnification of microglia. 
Quantitation of the fold change versus saline injected controls is presented in Panel D 
(FcγRII/III) and Panel H (SRA).   Scale bar = 500 µm, * p < .05 compared to saline 
injected controls.  
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Figure 20. FcγRII/III and SRA are induced by LPS but not inhibited by co-treatment with 
dexamethasone .   
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Based on previous findings that most RNAs peaked at 3 days (Herber et al., 
2004a), several markers were examined at that time point, as shown in Figure 21.  The 
relative expression of CD45 after LPS injection or LPS-dexamethasone co-treatment 
(compared to saline injected control mice) is shown in Figure 21A.  ANOVA revealed a 
significant effect of dose (F2,17 = 4.5, p = .03).  Post hoc analysis showed LPS 
significantly increased CD45 mRNA levels, which was inhibited by dexamethasone co-
treatment.  Results from post hoc analysis of the cytokine interleukin 1 beta (IL1β) levels 
also showed a significant increase due to LPS, which was ameliorated by dexamethasone 
(Fig. 21B).  In contrast, FcγRIIb (Fig. 21C) and SRA (Fig. 21D) mRNA were induced by 
LPS and unaffected by dexamethasone co-treatment.  ANOVA revealed a significant 
effect of treatment for both markers (FcγRIIb:  F2,17 = 4.8, p = .02; SRA: F2,17 = 8.4, p = 
.003).  Post hoc analysis showed LPS and LPS plus dexamethasone co-treatment groups 
were both significantly elevated compared to controls for FcγRIIb and SRA.  
 
Figure 21.  LPS stimulated gene transcripts have a pattern similar to protein expression. 
APP mice were injected with saline, LPS, or LPS with concurrent dexamethasone 
treatment for 3 days.  Graphs depict RNA analysis of the injected hippocampus compared 
to saline injected controls.  CD45 (A) and IL1β (B) transcripts were induced by LPS and 
inhibited by dexamethasone.  In contrast, FcγRIIb (C) and SRA (D) transcripts were 
induced by LPS but not inhibited by concurrent dexamethasone treatment. * p < .05. 
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Figure 21.  LPS stimulated gene transcripts have a pattern similar to protein expression. 
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Discussion 
Here we have shown the ability of the innate immune system to remove Aβ from 
the brains of APP transgenic mice.  Intrahippocampal injections of LPS reduced the total 
Aβ burden without affecting Congophilic plaques, confirming previous reports (DiCarlo 
et al., 2001; Herber et al., 2004b).  These findings indicate that the diffuse Aβ material is 
more sensitive to whatever mechanisms are activated by the LPS injection compared to 
compacted material.  As a first attempt to identify such mechanisms, we partially 
inhibited the inflammatory reaction to LPS injection with systemic dexamethasone 
administration.  This resulted in attenuation of the amyloid clearance by LPS, and a 
significant reduction in most microglial markers which were elevated by LPS.  Therefore 
it is likely that the glial reaction to LPS was responsible for the removal of diffuse Aβ.   
In an effort to characterize the glial response to LPS, we evaluated both general 
markers of activation (CD45 and CR3) as well as receptors involved in phagocytosis 
(FcγRII/III and SRA).  Though CD45, CR3, FcγRII/III, and SRA were all induced by 
LPS injection, only CD45 and CR3 were inhibited by subsequent dexamethasone 
treatment.  RNA analysis from the hippocampus of LPS injected versus LPS plus 
dexamethasone co-treated mice confirmed the immunohistochemistry results.  The 
inhibition of CD45 by dexamethasone has also been reported after anti-Aβ antibody 
treatment, thereby preventing antibody-mediated removal of Aβ (Wilcock et al., 2004a).  
Similarly, in another report, dexamethasone inhibited CR3 levels after LPS injection into 
the substantia nigra (Castano et al., 2002).  In contrast, glucocorticoids actually enhanced 
certain Fc receptor subtypes in some models (Kizaki et al., 1996; Sivo et al., 1993; 
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Yamaguchi et al., 2001).  We have previously shown that FcγRII/III and SRA expression 
after LPS injection was transient, peaking from 3-7 days and returning to baseline by 14 
days post injection (Herber et al., 2004a,b).  This was in stark contrast to CD45 and CR3 
which remained elevated out to 28 days post injection.  Promoter analysis of all four 
genes shows little similarity which may account for their differential regulation in 
response to LPS and glucocorticoid treatment (Grewal et al., 2001; Nishimura et al., 
2001; Timon & Beverley, 2001).  
Both microglia and astrocytes are capable of phagocytosing Aβ in vitro and in 
slice preparations   (Shaffer et al., 1995; Wyss-Coray et al., 2003).  The mechanism by 
which this is accomplished in vivo is unclear and as yet unproven.  Scavenger receptors, 
β-integrins, complement proteins, lipoprotein receptor related proteins, and receptors of 
advanced glycation end products can all bind Aβ and mediate endocytosis (Herz & 
Strickland, 2001; Huseman et al., 2002; Koehigsknecht & Landreth, 2004; Schmidt et al., 
2001).   Although FcγRII/III are increased in our LPS model, we have no direct evidence 
of antibody production, and upregulation of these receptors was probably due to the 
general activation of the cell in preparation for initiation of an acquired immune response 
(Amigorena et al., 1989; Iwasaki & Medzhitov, 2004; Keller et al., 1994; Laszlo & 
Dickler, 1990).  Though scavenger receptor B (SRB) has been implicated in AD (Coraci 
et al.., 2002), no information is available for SRA.  We previously examined SRB mRNA 
following LPS injection and saw only a small increase at 6 hr post injection, and 
therefore have shifted focus to SRA (Herber et al., 2004a).  SRA seems to be at least 
partially responsible for astrocyte- mediate amyloid removal, though similar results with 
microglia are not available (Wyss-Coray et al., 2003). 
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The implications of the glial response to LPS and dexamethasone are two-fold.  
First, cells do not require general activation in order to upregulate their expression of 
receptors capable of mediating phagocytosis.  However, in order to effectively clear out 
foreign or toxic materials (such as LPS, Aβ, etc.) general cell activation is necessary.   
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Conclusions 
Alzheimer’s disease was first described by Alois Alzheimer in 1907 in an article 
entitled, “On an Unusual Illness of the Cerebral Cortex.” In this seminal work, Alzheimer 
describes a 51 year old female patient who suffered from severe dementia.  Upon 
autopsy, her brain was examined and found to be grossly atrophied.  Histopathology 
revealed,  
 
“the nucleus and the cell itself disintegrate and only a tangle of fibrils indicates 
the place where a neuron was previously located… Many neurons, especially in 
the upper layer, have completely disappeared.  Distributed all over the cortex, but 
especially numerous in the upper layers, there are minute military foci which are 
caused by the deposition of a special substance in the cortex.” 
 
 The terms neurofibrillary tangles (NFT) and plaques, or senile plaques, have 
since been coined for the typical pathology of AD.  Additional aspects of the disease 
include inflammation and alterations in the cerebrovasculature (Akiyama et al., 2000; 
Rhodin & Thomas, 2001; de la Torre, 2002).  Several hypotheses have been proposed 
over the past century as to the cause of the disease.  Recent therapeutic developments aim 
to remove or prevent amyloid deposition, based on the amyloid hypothesis of AD.  This 
hypothesis proposes “amyloid deposition as the central event in the aetiology of 
Alzheimer’s disease” (Hardy & Allsop, 1991).  Such a view presumes neurofibrillary 
tangles, neurodegeneration, and inflammation (the other pathological components of AD) 
to be a consequence of amyloid deposition.   
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The major component of plaques is the Aβ peptide, which can aggregate to form 
amyloid deposits.  This peptide originates from the amyloid precursor protein (APP), as a 
result of proteolytic cleavage by beta- and gamma -secretases (Nunan & Small, 2002).  
The Aβ peptide varies in length from 37-43 amino acids.  Aβ1-40  is the predominant 
species, but Aβ1-42 is more hydrophobic and therefore more readily forms fibrils.  In 
support of the amyloid hypothesis are the discoveries of several genetic mutations, all of 
which cause enhanced deposition of amyloid and ultimately lead to autosomal dominant 
AD, particularly at a young age (pre-senile).  These mutations make up the portion of the 
population with familial Alzheimer’s disease, and account for approximately 5-10% of all 
AD cases.  In 1991 Goate and colleagues reported mutations located on human 
chromosome 21 which ultimately mapped to the APP gene.  A single amino acid 
substitution of valine to isoleucine, close to the carboxy terminus of the Aβ peptide, 
results in a more hydrophobic, and possibly more fibrillogenic, species with the added 
potential for enhanced gamma secretase cleavage.  Over the past 15 years, many 
mutations have been described near the c-terminus of Aβ, such as the Austrian, French, 
Florida, London, and Australian varieties (Nunan & Small, 2002).  Mutations located in 
the middle of the Aβ peptide cause cerebral amyloid angiopathy (Van Nostrand et al., 
2002).  A double substitution at the N-terminus of Aβ (K670N, M671L), known as the 
Swedish mutation, leads to enhanced cleavage by beta secretase, and is the genetic 
mutation used in the Tg2576 transgenic mice described in our studies (Hsiao et al., 1996).   
These mice show age- associated amyloid deposition, reactive gliosis, and cognitive 
impairments, much like AD.  Trisomy 21 leads to a triple dose of APP, and AD 
pathology can be seen in older Down’s patients, even though the gene is not mutated. 
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In 1995, mutations in two additional genes were identified as causal for AD.  
Sherrington and colleagues found missense mutations in the gene encoding presenilin 1 
(PS1), located on chromosome 14, which led to autosomal dominant AD.  That same year 
Levy-Lehad and colleagues reported mutations in a similar gene, presenilin 2 (PS2), 
located on chromosome 1, which also led to autosomal dominant AD.  Greater than 85 
mutations in the presenilins have been identified in familial AD.  Presenilin is part of the 
gamma -secretase complex, which proteolytically cleaves APP in conjunction with beta -
secretase to form Aβ (De Strooper, 2003).  Transgenic mice carrying a PS1 mutation 
(M146L, line 5.1) show little pathology, with no amyloid deposition (Duff et al., 1996).  
However, breeding the Tg2576 APP mice with PS1 mice leads to accelerated amyloid 
deposition and cognitive dysfunction in mice bearing both mutations compared to mice 
with mutations in APP only (Holcomb et al., 1998; Gordon et al, 2001; 2002). 
Associated with increased risk for AD are allelic forms of apolipoprotein E 
(APOE; Mahley & Huang, 2004).  There are three APOE alleles expressed in humans 
(APOE2, 3, and 4) which are involved in lipid and cholesterol transport and homeostasis.  
The predominant allele is APOE3.  Corder and colleagues identified a gene- dosing effect 
of the APOE alleles in 1993.  An increased risk of late onset (>65 years old)   
Alzheimer’s disease was associated with the E4 allele.  In cases of AD with APOE4, 
there is increased plaque and tangle density as well as an earlier age of onset compared 
with the E3 allele (Marz et al., 1996).  Although the mechanism remains uncertain, 
Colton and colleagues have demonstrated a link between the APOE4 allele and 
exaggerated innate immune activation (Colton et al., 2002a,b, 2004; Czapiga & Colton, 
2003).   
 111 
The genetic mutations associated with familial AD as well as the gene dosing 
effects of APOE4 all increase the amyloid burden of the brain and are causal or 
associated with increased risk of AD.  Though there are identifiable mutations in tau 
which cause tangle formation and lead to frontotemporal dementia or Pick’s disease, 
none of them are associated with AD (Friedhoff et al., 2000).  Thus, the genetic linkage 
to amyloid deposition has further strengthened the amyloid hypothesis of AD. 
Another approach to the study of AD is the inflammation hypothesis (McGeer & 
McGeer, 1995).  According to this line of reasoning, it is not the lesions in AD brain 
(plaques, tangles, and neuron loss) but rather the inflammatory response to such lesions 
that leads to neuron loss and the clinical manifestations of the disease.  Originally 
described by Celsus in the first century A.D., peripheral inflammation is characterized by 
rubor (redness), calor (heat), dolor (pain), and tumor (swelling).  These responses are 
secondary to the primary reaction of the tissue.  The primary process is characterized by 
both acute and chronic phases (Hardman et al., 2001).  During the acute phase, tissue 
damage causes the release of cellular contents which triggers changes in the local 
vasculature as well as migration of leukocytes and macrophages to the site. The 
infiltrating immune cells can then release chemical mediators such as histamine, 
prostaglandins, leukotrienes, and cytokines.  These chemical and cellular mediators of 
inflammation fight off infection as well as destroy damaged and infected cells.  There are 
three outcomes to injury: the host wins and inflammation is resolved, the host loses and 
dies, or there is a stalemate where chronic inflammation persists.   This chronic phase is 
characterized by macrophage activation and release of chemical mediators which can 
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ultimately cause tissue damage.  Typical examples of peripheral chronic inflammation are 
arthritis and inflammatory bowel disease. 
In the brain, swelling is the only secondary inflammatory response seen (no 
redness, pain, or heat).  Swelling is seen only under extreme circumstances such as after 
traumatic brain injury or during encephalitis.  However swelling is not seen in 
neurodegenerative conditions such as Alzheimer’s or Parkinson’s diseases, or multiple 
sclerosis.  Instead, a more subtle inflammatory process can predominate in the brain, as 
characterized by reactive glia and the products they produce.  A classic example of this 
type of silent brain inflammation is Alzheimer’s disease.  This process is mainly 
mediated by the innate immune system, with the endogenous microglia as the tissue 
specific macrophages.  B and T cells are largely absent from the brain and thus adaptive 
immune activation does not play a major role in the inflammation of AD (Akiyama et al., 
2000).  Similar to peripheral inflammation, there are acute and chronic inflammatory 
responses in the brain, resulting in microglial activation, release of chemical mediators, 
and the potential for neuron death.  Cell death in the CNS is problematic due to the fact 
that neurons do not divide/replicate, and there is little repopulation by stem cells.  If a 
neuron dies as a result of an inflammatory process, the lesion is permanent.   
The exact mechanism of neuron death due to inflammation is probably a 
combination of factors.  Reactive microglia, like all macrophages can produce a 
respiratory burst as well as cytotoxic elements such as complement proteins, cytokines, 
and prostaglandins (Colton et al., 1992; 2000; Colton & Gilbert, 1993; Colton & 
Chernyshev, 1996; Czapiga & Colton, 1996; Akiyama et al., 2000).  In vitro, release of 
this chemical milieu can be triggered by phagocytic activities and/or exposure to 
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complement proteins, cytokines, prostaglandins, and microbial products (such as LPS), as 
well as the Aβ peptide (McGeer & McGeer, 1995).  The respiratory burst (leading to 
release of oxygen free radicals and nitric oxide) causes oxidative damage to proteins and 
the subsequent stress leads to apoptotic cascades and neuron death.  The complement 
cascade, both classical and alternative, can ultimately lead to formation of the membrane 
attack complex which participates in cell lysis (Shen & Meri, 2003).  Cytokines and 
prostaglandins reinforce the reaction of microglia in a self perpetuating cascade as the 
inflammation remains unresolved.  The accumulation of amyloid deposits suggests that 
microglia are unable to remove the deposists.  Microglia are associated with amyloid 
plaques and may be experiencing “frustrated phagocytosis” as they are unable to effective 
clear the material (Colton et al., 2000; Fonsesca et al., 2004; Henson, 1971).  The 
microglia therefore remain activated in a chronic inflammatory response.  Though direct 
toxicity to neurons due to amyloid deposits and tangle formation is probable (Canevari et 
al., 2004; Davies, 2000), the progression may be slow without the additional 
inflammatory stimulus to intensify the process (McGeer & McGeer, 1995).  Bystander 
lysis may also occur whereby undamaged neurons are killed as a part of this 
uncontrolled/chronic inflammatory response.  Though reactive microglia have never been 
shown to kill healthy neurons in vivo, a chronic inflammatory cascade may be neurotoxic 
in AD.  McGeer and colleagues (1995) propose an autotoxic loop which could lead to 
neuron death, shown in Figure 22. 
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Figure 22.  Autotoxic mechanisms in Alzheimer’s Disease. 
 
 Supporting the inflammation hypothesis are studies showing multiple 
inflammatory cascades active in the AD brain including complement, cytokines and 
chemokines, prostanoids, acute phase proteins, and free radicals (Akiyama et al., 2000).  
Plaques and tangles are both inert, insoluble aggregates in vivo and glia mount an 
inflammatory response to these aggregates.  Studies in the 1980s of human post mortem 
AD brain showed reactive microglia and infiltrating T-cells (McGeer et al., 1987; 1988 
a,b; Itagaki et al., 1988).  Subsequently, the brain inflammatory response was correlated 
to AD and cognitive decline.  Lue et al. (1996) measured plaque and tangle load as well 
as inflammatory markers such as complement proteins and MHCII in three groups: 
normal controls, high pathology controls (HPC), and overt AD patients.  Both the HPC 
and AD brains had pathological diagnosis of AD with significant amounts of plaques and 
tangles.  However, the HPC group had no synaptic loss, no overall brain atrophy, and 
significantly less inflammatory reaction.  These findings led the authors to conclude: 
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“…of all the pathological variables examined, the best predictors of synaptic 
changes (i.e. the variables that accounted for the highest proportions of synapse variance) 
are those related to inflammation, C5b9 immunoreactivity, and activated LN3+ 
microglia.  Taken together, these data suggest that elderly patients may present at autopsy 
with profuse cortical plaques and entorhinal cortex NFTs but may not evidence synaptic 
loss unless these changes are accompanied by inflammatory reactions.  Inflammation 
may therefore be one of the final common pathways through which Aβ deposits and 
NFTs manifest their neurodegenerative effects…” 
 
A similar study in 2003 by Vehmas et al. demonstrated a change in gliosis associated 
with the transition from probable to definite AD.  Microgliosis was elevated in both 
groups compared to normal controls, with higher levels in the definite AD group.  
Astrogliosis was an even better correlate of the disease, with significantly elevated GFAP 
levels in definite AD compared to possible AD.  Inflammatory gliosis has proven to be a 
robust finding in AD brain, and is also seen in amyloid depositing transgenic mice 
(Gordon et al., 2002).  
In support of the inflammation hypothesis are several epidemiological studies 
showing a decreased risk for AD with anti-inflammatory drug use (reviewed in McGeer 
et al., 1996).  Early studies examined arthritis as a factor in AD and established an overall 
0.556 (osteoarthritis) and 0.194 (rheumatoid arthritis) odds ratio (OR) indicating 
decreased risk for AD and possible protective effects of the anti-inflammatory drugs 
commonly used by people with arthritis.  When drug use was considered as a factor in 
AD, both steroids (OR = 0.656) and NSAIDS (OR = 0.496) decreased AD risk.  A recent 
study conducted in the Netherlands considered exact drug and therapy duration as factors 
in AD (In ‘t Veld et al., 1998).  The odds ratio overall was 1.0.  However, when the data 
was stratified for age, a protective effect was seen in persons less than 85 years old (OR = 
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0.53).  Additionally, a greater protective effect was seen in patients with more than 6 
months NSAID use.  Thus, it seems that inhibiting inflammation could be beneficial in 
Alzheimer’s disease. 
Based on these findings, NSAIDs have been administered to amyloid depositing 
transgenic mice, with impressive results.  Ibuprofen and NCX-2216 (a nitric oxide 
donating flurbiprofen derivative) significantly reduced amyloid burden in doubly 
transgenic APP:PS1 mice (Jantzen et al., 2002).  Similar results for ibuprofen have been 
reported (Lim et al., 2000; Yan et al., 2003), and Eriksen et al. (2003) demonstrated that 
multiple NSAIDs reduced soluble Aβ in singly transgenic APP mice.  The actual Aβ 
lowering mechanism of NSAIDs is a matter of controversy (reviewed in Gasparini et al., 
2004).  In vitro, NSAIDS can inhibit Aβ aggregation, and decrease Aβ production.  
However, the Aβ lowering effects seem to be independent of cyclooxygenase (COX) 
activity as doses required to alter Aβ levels are much high than those necessary to 
inactivate the COX enzyme (Weggen et al., 2001).  The Aβ lowering effects fo NSAIDs 
also seem to be independent of PPARγ activity.  Ciglitazone, a PPARγ agonist, did not 
alter Aβ levels in vitro (Sagi et al., 2003), nor did pioglitazone affect amyloid deposition 
in vivo (unpublished data by Paul Jantzen in our lab).   
Several NSAIDs have been used in human trials to establish effects on AD, 
though results to date have been discouraging.  Rofecoxib, naproxyn, and a combination 
of diclofenac/misoprostol have all been eliminated as potential AD therapies in clinical 
trials (Aisen et al., 2003; Reines et al., 2004; Scharf et al., 1999).  Currently under 
clinical investigation are ibuprofen, indomethacin, and celecoxib, listed on the US 
government’s web site of active clinical drug trials ( http://clinicaltrials.gov). 
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However, not all inflammation is regarded as detrimental.  As mentioned 
previously there are three potential outcomes to injury/insult:  the host wins and 
inflammation is resolved, the host loses and dies, or a stalemate is reached and chronic 
inflammation ensues.  The first outcome (the host wins, tissue is repaired, and 
inflammation is resolved) reveals the protective side of inflammation.  In the brain, 
reactive glia can aid in removal of pathogens and cellular debris, as well as supply trophic 
factors.  In AD, a key therapeutic strategy uses vaccination against the Aβ peptide and 
stimulates the immune system resulting in decreased amyloid burden (reviewed later in 
this discussion).  Therefore, stimulating the immune system, including microglia, 
represents a potential means of removing brain amyloid in AD. 
The model we used for the studies described in this dissertation combined both 
the amyloid and inflammation hypotheses of AD in an effort to create a system that more 
closely resembled the human condition.  We injected the inflammatory agent 
lipopolysaccharide (LPS) into the hippocampus of various transgenic mice, in particular 
amyloid -depositing APP mice.  LPS triggers the innate immune response leading to 
inflammation.  The expected outcome was enhanced amyloid burden and/or neuron 
death, similar to that seen in human AD brain. 
In the first study, we examined α7 nAChRs in amyloid- depositing mice and 
during neuroinflammatory conditions. Our desire to evaluate nicotinic receptors was 
based on several observations.  First, cholinergic signaling is impaired in AD with 
declines in α7 nAChRs among other populations (Perry et al., 2001).  Second, there have 
been numerous reports of nicotine’s protective effect for AD (reviewed in Rusted et al., 
2000), and nicotine administration reduced the amyloid burden in APP transgenic mice 
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(Hellstrom-Lindahl et al., 2004; Nordberg et al., 2002).  Third, a subset of nicotinic 
receptors, those containing α7 subunits, can interact with the Aβ peptide.  In vitro, Aβ 
binds to α7 nAChRs and blocks the receptor, altering calcium homeostasis and 
potentially impairing neuronal signaling (Dineley et al., 2001, 2002a,b; Grassi et al., 
2003; Pettit et al., 2001; Wang et al., 2000a,b).  In APP transgenic mice, there are reports 
of decreased α7 nAChRs in older animals, which correlated with amyloid burden and 
cognitive impairments (Dineley et al., 2001, 2002a,b).  Lastly, α7 nAChRs have been 
implicated in the inflammatory response.  In human AD brain, reactive astrocytes co-
localize with amyloid plaques and label for α7 nAChRs (Teaktong et al., 2003).   There is 
also evidence that microglia can expresss α7 nAChRs (Shytle et al., 2004).  These 
nicotinic receptors have also been studied in the peripheral immune system.  Wang and 
colleagues demonstrated that α7 negatively regulates inflammation, as α7 knock out 
mice showed an enhanced inflammatory response to LPS challenge versus wild type mice 
(2003).   
Based on the potential of α7 nAChRs to interact with Aβ, we further investigated 
this relationship in our model of LPS induced neuroinflammation (Herber et al., 2004c).  
We used several commercially available antibodies to detect α7 nAChRs by 
immunohistochemistry and Western blotting.  We saw no changes in 
immunohistochemical labeling of neurons for α7 when comparing amyloid depositing 
mice (APP, APP:PS1) to nontransgenic mice, in contrast to previous reports (Dineley et 
al., 2001, 2002a,b).  However, we confirmed the findings of Teaktong and colleagues by 
showing α7 nAChR immunoreactive astrocytes which co-localized with Congophilic 
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deposits in APP and APP:PS1 mice.  In order to determine if this was a result of α7 
interacting with Aβ, or part of a more general inflammatory response, we injected LPS 
into the hippocampus of several mouse models (nontransgenic, APP transgenic, and α7 
knock out mice).  This treatment resulted in substantial astrogliosis and immunolabeling 
by α7 antibodies as determined by immunohistochemistry, in all genotypes tested.  These 
results were compared to Western blot, DNA, and RNA analysis and established the 
nonspecificity of the α7 antibodies.  Recent reports have confirmed the nonspecificity of 
not only α7 but also α4 nAChR antibodies (Moser et al., 2004).  Current work by 
Dineley and colleagues showed decreased soluble Aβ in APP mice crossed with the α7 
knockouts, thus there may be some role for α7 in Alzheimer’s disease, though 
determining the exact mechanisms will require rigorous testing protocols  (Dineley et al., 
2004). 
The remaining chapters of this dissertation looked at the contribution of glia to the 
brain inflammatory response in order to gain insight from reactive gliosis and apply that 
information to the pathological processes of AD.   Neurons, astrocytes, and microglia all 
contribute to the inflammatory response seen in AD, though the precise role of each cell 
type in this reaction is unclear.   
In the earlier part of the twentieth century, Rio-Hortega proposed that microglia 
are the resident macrophages of the central nervous system (1932).  Microglia are 
immunocompetent and act as mediators of innate immunity, but can also present antigen 
as part of the adaptive immune response (Streit, 2002). Similar to peripheral 
macrophages, microglial activation has both toxic and protective roles, thus these cells 
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are likely candidates for mediating inflammation, neurotoxicity, and/or Aβ removal in 
AD brain.  Activated microglia can produce many neurotoxic species such as 
complement proteins, cytokines, prostaglandins, and reactive oxygen species (Akiyama et 
al., 2000).  In 1996 Kreutzberg described various microglial activation states. Activated 
microglia undergo dramatic changes in morphology, and these changes are possibly 
linked to phagocytic versus antigen presenting functions.  Hauss-Wegrzyniak and 
colleagues have also described a “bushy” phenotype that arises during chronic LPS 
infusion into brain ventricles (1998).  Streit and colleagues (1999) have proposed the 
following phenotypes for reactive microglia, shown in Figure 23. 
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Figure 23. Microglial activation states.  Neuronal injury can trigger injury signals which 
activate resting (ramified) microglia.  The branches of these cells can become swollen 
(reactive/activated) or hyper-ramified (an intermediate stage).  Microglia can also further 
activate and become phagocytic. 
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In general, the microglial inflammatory response to amyloid deposits is viewed as 
harmful (Akiyama et al., 2000).  In vitro studies have demonstrated the neurotoxic 
properties of both Aβ peptides as well as inflammatory mediators such as cytokines and 
reactive oxygen species (Canevari et al., 2004; Small et al., 2001; Walsh et al., 2002).  
However, in vivo neurodegeneration due to either Aβ or inflammation has been difficult 
to demonstrate.   
Intracranial administration of LPS has been used historically as an in vivo model 
of neuroinflammation, activating both microglia and astrocytes.  LPS is bound by the 
LPS binding protein which can then associate with CD14 and TLR4 to transduce a signal 
through the cell (Heumann & Roger, 2002; Thomas et al., 2002).  Several pathways are 
activated including NFκB, resulting in gene transcription and the ultimate production of 
inflammatory mediators (Sen & Baltimore, 1986).  The LPS signaling cascade is 
illustrated in Figure 24. 
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Figure 24.  Lipopolysaccharide signaling cascades.  Lipopolysaccharide (LPS) is bound 
in the circulation by  LPS binding protein (LBP).  This complex then interacts with cell 
membrane associated CD14 and toll like receptor 4 (TLR4) to transduce an intracellular 
signal.  Various kinase cascades are induced (such as p38MAPK and IκκB) leading to the 
activation of transcription factors  including STAT, AP1, and NFκB.  Down stream 
targets include cyclooxygenase (COX), nitric oxide synthase (iNOS), and superoxide 
dysmutase (SOD).  Ultimately inflammatory mediators are produced such as prostanoids, 
nitric oxide (NO), tumor necrosis factor (TNF), and interleukins (IL). 
Extracellular 
Intracellular 
LBP
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Chapters 2 and 3 of this dissertation looked at the time course of glial activation 
after LPS administration into either nontransgenic mice or APP transgenic mice.  Several 
markers of gliosis were examined including CD45, complement receptor 3 (CR3), Fcγ 
receptors, scavenger receptors, and GFAP.  Both sides of the inflammatory response - 
toxic versus protective - were evaluated. 
Brain inflammation begins with the glial response to insult.  Once cells are 
activated, they can produce inflammatory agents which can be cytotoxic.  LPS 
administration into both transgenic APP and nontransgenic mice led to acute and chronic 
microglial activation (Herber et al., 2004a,b).  Two proteins, CD45 and CR3 were 
upregulated beginning as early as 24 hours after injection of LPS, and remained 
upregulated after 28 days.  Resting and reactive microglia express these two proteins, and 
thus CD45 and CR3 are considered markers of general microglial activation.  CD45 
(leucocyte common antigen, LCA) is a protein tyrosine phosphatase.  The endogenous 
ligand and the exact functioning of this protein in inflammation are unknown (Irie-Sasaki 
et al., 2003).  Complement receptor 3 (CR3, CD11b, MAC-1) is a β2 integrin which 
mediates cell adhesion (Ehlers, 2000).  In addition to the extracellular matrix, a 
prominent endogenous ligand for CR3 is complement component C3b1.  Downstream 
activation pathways include MAP kinase activation and ultimately actin reorganization, 
promoting migration and phagocytosis.  It is noteworthy that CR3 may also bind to LPS, 
thus activating the alternative pathway.  In our studies, large increases in the levels of 
CD45, CR3, and the cytokines IL1β and TNFα were seen after a single injection of LPS, 
indicating a significant inflammatory response.  A spreading wave of inflammation was 
noted with the injected hippocampus responding first, then adjacent cortices and the 
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striatum, and ultimately the entire brain (including frontal cortex and brainstem) showed 
microglia expressing high levels of CD45 and CR3.  A surprising finding was the 
continued expression of these two proteins in the hippocampus by microglial cells 28 
days after LPS injection.  This may indicate a state of vigilance by the microglia, with the 
cells primed for future action.   
Changes in cell morphology at various time points after LPS injection was 
examined with CD45 and CR3 immunostaining.  Untreated nontransgenic mice had 
microglia which were faintly stained for CD45/CR3 and had a ramified appearance with 
fine delicate processes.  In untreated amyloid depositing mice (APP, APP:PS1), the 
microglia showed increased staining and had a bushy, reactive phenotype in association 
with deposits.  After LPS administration, the microglia increased both CD45 and CR3 
expression.  Some had shorter, thicker, branched process, with a bushy shape, and were 
seen throughout the time course after LPS injection.  Other cells were round or ameboid 
and were only transiently seen from 1-7 days after LPS.  Though resting microglia can be 
distinguished from peripheral macrophages by their branched shape, round and/or 
ameboid microglia are impossible to discriminate from peripheral macrophages.  Thus, in 
vivo it is difficult to determine which exact cell type is being evaluated because all 
macrophages express similar markers.  It is also difficult to draw correlations from 
studies conducted in vitro.  It is currently not possible to culture adult mouse microglia, 
thus neonatal or immortalized microglial cell lines are typically used (Yao et al., 1990; 
Colton et al., 1991; 1992a,b; Colton & Gilbert, 1993; Kopec & Carroll, 1998).  Studies 
using adult versus neonatal mouse astrocytes however show vast differences between the 
two populations, and similar disparities can be assumed for microglia (Wyss coray et al., 
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2003; Paul et al., 2004).  Thus, though microglia clearly become activated, produce 
inflammatory mediators, migrate, proliferate, phagocytose, and present antigen in vitro, 
the same functions are not as clear in vivo.   
Though a widespread, significant inflammatory response was seen, neuron death 
was not observed in any of our studies.  This is different from the brain’s response to 
chronic LPS administration.  Several publications by Wenk and Hauss-Wegrzyniak and 
colleagues over the past 15 years have demonstrated the effects of chronic infusion of 
LPS into the fourth ventricle of rats (Hauss-Wegrzyniak et al., 1998a, b; 2000; 2002; 
Willard et al., 1999).  Their protocol led to significant astro- and microgliosis as well as 
forebrain cholinergic neuron death. In contrast, acute LPS injection into the brain 
parenchyma such as the anterior cortex and hippocampus does not triggered cell death, as 
demonstrated by our lab and others (DiCarlo et al., 2001; Herber et al, 2004a,b; Kim et 
al., 2000).  However the substantia nigra, a part of the dopaminergic system implicated in 
the pathogenesis of Parkinson’s disease, is susceptible to the degenerative inflammatory 
effects of acute LPS administration (Castano et al., 2002; Kim et al., 2000).  In our own 
studies, acute intrahippocampal LPS administration did not cause detectable 
neurodegeneration as determined by cresyl violet and fluorojade staining, nor was 
synaptic dysfunction detected by synaptotagmin levels, regardless of dose, time, or 
genotype examined (Herber et al., 2004a,b).  LPS injection induced NFκB expression 
(unpublished data) which has been linked to neuronal survival, and thus may be 
protective under the conditions of our protocol (Kassed et al., 2004).  The only conditions 
which caused neuron death were co-injections of LPS and interferon gamma 
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(unpublished data).  It is possible that the presence of both endogenous and exogenous 
inflammatory mediators are necessary to kill cells. 
The protective aspects of microglial activation include neurotrophic support, as 
well as clearance of cellular debris, foreign substances, and microbial components.  
Microglia have demonstrable phagocytic functions, similar to peripheral macrophages 
(Kalmar et al., 2001; Yao et al., 1990; Czapiga & Colton, 1999).  In our studies, 
stimulation of the innate immune system by intrahippocampal injection of LPS led to 
time-dependent reductions in Aβ levels by as much as 70% (Herber et al., 2004b).  The 
reductions in Aβ were transient, occurring between 3 and 14 days after LPS injection, 
then returning to baseline levels after 28 days.  Diffuse Aβ material, but not compacted 
Congophilic deposits, were decreased after LPS treatment (it is interesting to note that 
stimulating microglia using an Aβ antibody reduced both diffuse and compact deposits in 
a similar protocol; Wilcock et al., 2003; 2004a,b).  The time course of Aβ reductions 
after LPS injection was closely related to the expression of microglial phagocytic markers 
and changes in cell morphology.  We therefore believe that the microglia are removing 
the Aβ, thus performing their protective phagocytic function.   
Other research groups have administered LPS to accelerate Aβ deposition, 
activate glia, and trigger neurotoxicity.  The experimental conditions of reports vary 
including the type and age of transgenic animals used; type, dose, and route of 
administration of LPS; and post- injection survival time.  In some cases amyloid 
deposition was triggered (Qaio et al., 2001; Sheng et al., 2003; Sly et al., 2001), while in 
others amyloid clearance resulted (DiCarlo et al., 2001; Quinn et al., 2003).  When 
considering the species of Aβ1-40 and Aβ1-42, the main indicator of Aβ reduction seems to 
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be closely related to plaque load and survival time.  Aged animals with significant 
amyloid deposits, surviving several days post injection, showed clearance of Aβ deposits 
after LPS treatment.  Compact plaques detected by either Congo red or thioflavin-S 
staining were inconclusively affected.  
In our studies, we examined markers of a phagocytic microglial phenotype 
including Fcγ and scavenger receptors at various time points after LPS injection.  Resting 
microglia do not express appreciable levels of Fcγ receptors, though some plaque 
associated microglia in APP mice do stain positively for the receptors.  After LPS 
injection, both protein (FcγRII/III) and mRNA (FcγRII) levels increased, peaked between 
24-72 hours, and then returned to low basal levels after a week.  Fc receptors are 
traditionally linked to adaptive immune responses, with the Fc portion of the 
antibody:antigen complex as the ligand (reviewed in Gessner et al., 1998).  The bound 
complex can then be internalized, processed, and antigen presented via MHCII.  The 
ligand for Fcγ receptors is IgG and there are three classes, with class I a high affinity, and 
classes II and III low affinity receptors.  Class I and III are activating; class II is 
inhibitory.  The various functions of Fcγ receptors as listed in the Gessner review include, 
“clearance of antigen/antibody immune complexes, regulation of antibody production, 
enhancement of antigen presentation, antibody-dependent cell-mediated cytotoxicity, 
phagocytosis, degranulation, and activation of inflammatory cells.”  There is evidence 
that peritoneal macrophages and B-cells express FcγRII after treatment with LPS, even in 
the absence of antibody:antigen complexes (Amigorena et al., 1989).  Microglia and bone 
marrow derived macrophages can also be induced to express Fc receptors after LPS or 
interferon gamma treatment (Keller et al., 1994; Loughlin et al., 1993).   In the 
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experiments described herein, the innate immune system is involved, but we would not 
expect antibody production as part of an acquired immune, thus Fc expression might be 
part of a general inflammatory response, priming the cell for phagocytosis should an 
adaptive response be mounted.   
Scavenger receptors A and B are also involved in the recognition of LPS by the 
innate immune system and can mediate clearance of bacteria and viral components.  In 
our studies, only a brief, mild increase in SRB mRNA was seen at 6 hr after LPS 
injection.  We were unable to confirm SRB expression by immunohistochemistry as 
available antibodies showed nonspecific staining patterns.  In contrast, a significant, 
thirty fold increase in SRA was seen both in mRNA and protein levels. Resting microglia 
did not express appreciable levels SRA, nor did plaque associated microglia in untreated 
APP mice.  After LPS injection, SRA increased with widespread expression, peaked 
between 24-72 hours, and then returned to low basal levels after a week.  The cell 
population staining for SRA appeared to be microglia/macrophages based on their 
morphology, rather than astrocytes.   
Scavenger receptors are traditionally linked to lipid metabolism and innate 
immune responses (Husemann et al., 2002; Kreiger et al., 2001; Febbraio et al., 2001; 
Platt and Gordon, 2001).  They are also called pattern recognition receptors as they 
nonspecifically recognize many bacterial and viral components, usually based on the 
presence of polyanionic ligands.  Both microglia and astrocytes can express various 
scavenger receptors, depending upon age and activation state of the cell.  Scavenger 
receptors A and B have been implicated in AD with increased expression in glial cells 
surrounding amyloid deposits (Coraci et al., 2002).  We were interested in SRA 
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specifically because it has been shown to bind both LPS and Aβ, though other scavenger 
receptors can also bind Aβ (Husemann et al., 2002).  Based on our results, we propose 
that LPS induced expression of scavenger receptors that could then bind Aβ and mediate 
removal.  A diagram constructing the results from chapters 2 and 3 is found in Figure 25. 
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Figure 25.  Mechanisms of LPS stimulated inflammation and Aβ removal.  This cartoon 
is a composite of various stained sections. A cresyl violet stain of the neurons in the 
dentate gyrus (upper left corner) and portions of CA3 (lower left corner) are the backdrop 
of the figure (the cells are stained blue).  Aβ deposits are stained brown, with compacted, 
Congophilic deposits stained red.  A reactive astrocyte (stained for GFAP) is shown in 
the upper right corner.  Microglia are stained for CD45 and are black, shown transitioning 
among various activation states.  LPS injection increases levels of the cytokines IL1β and 
TNFα, as well as cell surface receptors CD45, CR3, SRA, and FcγRII/III.  The graph in 
the upper left corner illustrates the changes over time in CD45/CR3 (purple), SRA and 
FcγRII/III (green) and Aβ (orange). 
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The final chapter of this dissertation sought to further confirm that microglia are 
involved in the LPS-stimulated removal of Aβ.  We used dexamethasone co-treatment 
with LPS intrahippocampal injection, thereby blocking microglial activation.  
Dexamethasone is a potent glucocorticoid anti-inflammatory agent with similar 
physiological activities as cortisone (Hardman et al., 2001).  Dexamethasone is bound in 
the circulation by corticosteroid binding globulin.  Dexamethasone can then transverse 
the cell membrane as it is hydrophobic.  Once inside the cell, dexamethasone binds to the 
glucocorticoid receptor in the cytosol, releasing inhibitory heat shock proteins from the 
glucocorticoid receptor allowing it to translocate to the nucleus.  Glucocorticoid 
receptor:dexamethasone complexes can then antagonize NFκB response elements (as 
well as others), thereby inhibiting the inflammatory response. 
In this final study, LPS induced the prototypical inflammatory response discussed 
previously.  CD45, CR3, and IL1β levels were increased, as well as SRA and Fcγ 
receptors.  Concurrent with this response, we demonstrated the expected decrease in the 
diffuse Aβ load, with no effect on compact deposits.  Dexamethasone co-treatment 
significantly inhibited CD45, CR3 and IL1β levels.  The reductions in diffuse Aβ caused 
by LPS were also inhibited by dexamethasone co-treatment, thus implicating the 
microglial response in the removal process.  However, neither FcγR nor SRA were 
inhibited by dexamethasone co-treatment.  These findings were confirmed by both 
immunostaining and mRNA analysis where possible.   
Dexamethasone’s ability to inhibit reactive microgliosis is well documented.  Our 
lab has previously demonstrated that CD45 levels (induced by intracranial injection of 
Aβ antibodies into APP mice) were significantly inhibited after dexamethasone treatment 
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(Wilcock et al., 2004a).  Others have shown that dexamethasone inhibits IL1β after either 
LPS or Aβ intraventricular injection into nontransgenic mice (Szczepanik & Ringheim, 
2003).  Thus, our findings that dexamethasone inhibited CD45, CR3, and IL1β and also 
subsequently prevented the removal of Aβ were expected.  These data provide evidence 
that general microglial activation, as demonstrated by CD45 and CR3 levels, is required 
for the removal of Aβ in our protocol. 
The lack of inhibition of Fc and scavenger receptors in the LPS-dexamethasone 
co-treated mice was an unexpected result.  There is evidence to support these findings.  
Of all the markers examined, only FcγR class II have an identified a glucocorticoid 
response elements (GRE) in the promoter (Hogarth et al., 1991).  In this case, the Fc 
receptor is inhibitory and the GRE is stimulatory, thus we would expect an increase in the 
levels of the class II receptor under dexamethasone- treated conditions.  Sivo and 
colleagues reported similar results where interferon gamma- stimulated FcγRII/III 
expression, and was not inhibited by dexamethasone treatment (1993).  A review of the 
literature did not reveal any data concerning dexamethasone’s effects on SRA expression.  
Taken together, the continued expression of FcγR and SRA after dexamethasone 
treatment indicates that expression of markers associated with phagocytosis are not 
sufficient to effect removal of Aβ in our protocol.  Figure 26 illustrates our findings to 
date.   
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Figure 26.  Mechanisms of LPS stimulated inflammation and Aβ removal, and inhibition 
by dexamethasone.  This cartoon is a composite of various stained sections (details 
provided in Figure 25). LPS injection increases levels of the cytokines IL1β and TNFα, 
as well as cell surface receptors CD45, CR3, SRA, and FcγRII/III.  Dexamethasone co-
treatment inhibited IL1β, CD45, and CR3, and also prevented Aβ reductions, but had no 
effect on SRA or FcγR levels.  The graph in the upper left corner illustrates the changes 
over time in CD45/CR3 (purple), SRA and FcγRII/III (green), and Aβ (orange). 
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Our current hypothesis is that microglia are removing the diffuse Aβ in our in 
vivo model.  This idea is supported by the finding that dexamethasone inhibited 
microglial activation and Aβ removal.  There are other possible explanations for 
dexamethasone’s action in our model.  The three experimental groups evaluated in our 
final study were a) saline injected controls, b) LPS injected, and c) LPS injected plus 
dexamethasone treated APP mice.  We did not evaluate dexamethasone-only treated 
mice; we were looking for the drug’s effect on LPS-induced inflammation, not 
dexamethasone’s effect on amyloid burden.  There are no published studies looking at 
glucocorticoid administration to amyloid depositing mice in the absence of other 
stimulating agents.  Human trials with prednisone did not ameliorate symptoms (Aisen et 
al., 2000).  In vitro, neither prednisone nor dexamethasone lowered Aβ (Sagi et al., 
2003).  NSAIDS, which can lower Aβ in vitro and in long term studies with mouse 
models, do not have reproducible effects after short term treatment (3-5 days; reviewed in 
Gasparini et al., 2004).  Therefore, it is unlikely that in the short time frames studied 
herein (3 and 7 days) dexamethasone would exert an appreciable effect on brain amyloid 
burden.  However, it cannot be ruled out that the effects we saw here were due to the 
potential for dexamethasone to increase Aβ burden thus negating the effects of LPS.  
Alternatively, dexamethasone can decrease the permeability of the blood brain barrier, 
which may have prevented the flux of Aβ from the brain to the periphery (Romero et al., 
2003).  Future studies could evaluate dexamethasone’s effect on amyloid deposition in 
the absence of inflammation, as well as the effects of other anti-inflammatory drugs on 
microglial activation and Aβ reductions. 
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Our primary hypothesis regarding the removal of Aβ centered on the scavenger 
receptors. Based on our results, we proposed that LPS induced expression of scavenger 
receptors that could then bind Aβ and mediate removal.  However, we found that SRB 
was not highly upregulated, and that SRA expression persisted in the absence of Aβ 
removal.  Therefore, a working hypothesis regarding LPS-stimulated reductions in Aβ 
can be proposed:  It is not the mere presence of the LPS molecule, nor is the upregulation 
of receptors involved in phagocytosis sufficient for Aβ removal.  Rather, general cell 
activation is required.  Thus, a phagocytic cell must not only bind Aβ (by various 
receptors) but must also be capable of engulfing the material (via general cell activation). 
There are several cell surface receptors grouped under the general classification of 
scavenger receptors which can bind Aβ, including SRB, CD36, SRA, CD68, receptor of 
advanced glycation end products, and lipoprotein receptor related protein (Peiser et al., 
2002; Huseman et al., 2002).  SRB clearly interacts with Aβ and can mediate microglial 
activation (Coraci et al., 2002; Moore et al., 2002; El Khoury et al., 2003). There is some 
confusion as to the identity of SRB and CD36 (a class B type receptor).  They are the 
focus of separate lines of research, but the sequences listed in Genbank are identical, and 
the nomenclature overlaps in the literature.  For the work described herein, we used the 
sequence for murine CD36, and have referred to it as SRB throughout.  Wyss-Coray and 
colleagues have shown that blocking SRB1 had no effect on astrocyte-mediated Aβ 
clearance (2003).  Whether there is truly a difference between CD36 and SRB, and the 
potential roles for either receptor in LPS stimulated Aβ removal remains to be elucidated.  
Future studies could block scavenger receptors with fucoidan, or specific antibodies, to 
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further evaluate their role in our model.  Scavenger receptor knockout mice for both 
CD36 and SRA are also available and could be bred with APP mice to test subsequent 
effects on LPS mediated Aβ removal. 
  CD68 (macrosialin) is another scavenger receptor implicated in the pathogenesis 
of AD.  The endogenous ligands for CD68 are modified lipoproteins and it is commonly 
referred to as a late endosomal or lysosomal protein, though cell surface expression also 
occurs (Ramprasad et al., 1996; Holness et al., 1993).  It has been shown to be 
upregulated in AD brain and in APP mice (Bornemann et al., 2001; Sasaki et al., 2002).  
We have briefly examined CD68 immunostaining in our model and found both plaque-
associated microglia as well as LPS-induced widespread expression of CD68 
(unpublished data).  This protein may be marking a phagocytic population and deserves 
further investigation. 
The receptor for advanced glycation end products (RAGE) has been intensely 
investigated in AD (Zlokovic et al, 2004).  Endogenous ligands for RAGE include 
nonenzymatically glycated adducts, beta -pleated sheet structures, and Aβ.  Rather than 
triggering Aβ removal via endocytosis, stimulation of RAGE leads to prolonged cell 
activation (Schmidt et al., 2001).  RAGE is upregulated in AD brain, particularly around 
plaques, and has been proposed to mediate the flux of Aβ from the periphery into the 
brain, thereby altering the balance between deposition and removal.  Lipoprotein receptor 
related protein (LRP) is thought to act as counterpoint to RAGE by mediating flux of Aβ 
out of the brain into the periphery with APOE mediating binding to the receptor.  The 
main ligands for LRP are modified lipoproteins, but this receptor can also bind bacterial 
and complement components.  In vitro models have shown that LPS decreased 
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macrophage LRP expression, whereas dexamethasone increased LRP levels (Laithwait et 
al., 1999; Marzolo et al., 2000). The effects in vivo remain to be elucidated thus LRP is 
an attractive target for investigation in our model of LPS mediated removal of Aβ.  
Future studies to further elucidate the Aβ removal described herein would evaluate each 
of these proteins under both LPS and dexamethasone treatment conditions. 
An alternative explanation is that scavenger receptors or phagocytosis in general 
may not be involved at all.  Other mechanisms of  Aβ removal include non scavenger 
receptor-mediated phagocytosis, decreased APP processing, increased proteolytic 
degradation of Aβ, or contributions from the periphery in clearance.   
Integrins mediate cell adhesion to both the extracellular matrix and to other cells, 
triggering intracellular signaling.  The α6β1 integrin is expressed by macrophages and 
binds Aβ in vitro as part of a trimolecular complex and mediates phagocytosis 
(Bamberger et al., 2003; Koenigsknecht & Landreth, 2004).  The trimolecular complex 
includes  α6β1, CD36, and CD47 (an integrin associated protein).  Though we 
investigated CD36 (SRB) in our model, we have not yet evaluated the roles of α6β1 or 
CD47 and this remains a potential route of LPS mediated Aβ removal.  CR3 is another 
integrin (β2) and is the receptor for complement component C3.  CR3 is a pattern 
recognition receptor which can bind LPS (Ehlers et al., 2000), though no data on its 
ability to bind Aβ was found after a literature search.  Complement protein C3 is a major 
component of the alternative pathway.  Wyss-Coray and colleagues have shown that 
inhibiting C3 led to increased Aβ deposition in transgenic mice (2002).  In our studies, 
CR3 was upregulated by LPS, and inhibited by dexamethasone, mirroring the effects on 
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Aβ removal.  Therefore CR3 could be directly involved in Aβ  reductions in our model.  
Future studies could inhibit the integrins using invasin and evaluate subsequent effects on 
Aβ levels.   
Several metalloproteinases have been shown to degrade Aβ, including neprilysin 
(NEP), insulin degrading enzyme (IDE), and matrix metalloproteinase 9 (MMP-9).  NEP 
is capable of degrading many circulating peptides including enkephalin, substance P, and 
Aβ.  NEP polymorphisms have been linked to increased risk of AD (Sakai et al., 2004), 
and transgenic mouse models have confirmed that overexpression of NEP can reduce 
brain Aβ levels (Mohajeri et al, 2004; Iwata et al., 2004). We conducted a preliminary 
investigation to determine NEP levels after LPS injection in our model.  We did not find 
any significant changes in the immunostaining patterns (unpublished findings).  Kaneko 
and colleagues have evidence that LPS decreases NEP levels in neutrophils, though 
effects on other macrophage populations are unknown (2003). Another enzyme, IDE, 
degrades both insulin and Aβ.  Based on the relationship between diabetes mellitus and 
AD, an increased risk for AD was found with certain variants of the IDE gene, and IDE 
activity, levels, and mRNA are decreased in AD brain (reviewed in Zhao et al., 2004).  A 
search of the literature did not reveal data reporting the effects of LPS on IDE levels, and 
we have not looked in our studies.  A separate class of metalloproteinases is associated 
with the extracellular matrix, and has been implicated in plaque formation in 
cardiovascular and Alzheimer’s diseases.  MMP-1, -3, and -9 are capable of degrading 
Aβ, and the levels of these enzymes are altered in AD brain (Leake et al., 2000; 
Helbecque et al., 2003; Yoshiyama et al., 2000).  Woo and colleagues recently showed 
that LPS can induce expression of MMP-9 in macrophages (2004), and thus may be 
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partially responsible for the reductions in Aβ in our model.  Future studies should include 
evaluation of these enzymes in our model. 
One simple explanation for the decreased Aβ load in our model is decreased 
levels of APP or its processing.  In an attempt to answer this question, we immunostained 
for APP and also measured mRNA levels after LPS administration (data not shown).  The 
immunostaining pattern was found to be nonspecific, and no significant changes in APP 
mRNA levels were found in response to LPS.  Thus we do not believe there were large 
changes in APP levels which could account for the up to 70% decreases in Aβ seen in our 
studies.  In general, most research regarding the brain’s response to insult indicates that 
APP levels increase, and presenilin is also induced (Pennypacker et al., 1999; Brugg et 
al., 1995; Siman et al., 1989; Wright et al., 1999; Sheng et al., 2003).  In other studies, 
LPS was shown to increase neuronal levels of Aβ species, though the researchers did not 
specifically examine the secretases (Sheng et al., 2003; Sly et al., 2001).  The activity or 
levels of alpha, beta and/or gamma secretases may be altered after LPS injection, which 
could account for the decreased levels of Aβ in our model.  We did not measure the 
secretases, thus such studies represent future lines of investigation.   
Another unexplored option in the LPS- mediated Aβ removal is the transcription 
factor peroxisome proliferator-activated receptor (PPARγ).  PPARγ is traditionally 
associated with lipid and insulin metabolism and is targeted in therapies for Type II 
diabetes, but also has potent anti-inflammatory actions.  Camacho and colleagues 
recently reported in an in vitro assay that the PPARγ agonists rosiglitazone and 
pioglitazone reduced Aβ secretion from APP transfected HEK cells (2004). However, our 
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own lab failed to demonstrate reductions in amyloid burden after pioglitazone 
administration to transgenic mice (Paul Jantzen et al., unpublished results.)  In another 
study using rats, PPARγ was down- regulated by peripheral LPS treatment (Ohata et al., 
2004).  However, the effects of intracranial administration of LPS are unknown and thus 
PPARγ represents another potential mechanism mediating Aβ reductions. 
Contributions of the peripheral immune system to the reductions in Aβ in our 
model cannot be ruled out.  There is evidence of peripheral blood- borne cells in the 
brains of our LPS injected mice as seen in the small round cells seen between 24 and 72 
hours after LPS injection.  As much as 80% of these cells may be recruited monocytes 
(Montero-Menei et al., 1996).  In order to rule out peripheral cells as mediators of Aβ 
removal, we could irradiate the mice or chemically ablate their bone marrow cells, and 
then inject LPS and monitor subsequent effects on Aβ burden.  Another potential 
mechanism of Aβ reductions can be found in the peripheral sink hypothesis (Matsuoka et 
al., 2003).  According to this line of thinking, Aβ levels can be reduced by creating a 
concentration gradient down which Aβ would move out of the brain and into the 
periphery.   LPS has been shown to disrupt the blood brain barrier and may therefore alter 
Aβ trafficking (Nonaka et al., 2005).  We did not evaluate the levels of Aβ in the 
periphery and therefore do not know the contribution of any potential sink in our model.  
Future studies could collect blood from the mice after treatment and evaluate the levels of 
Aβ. 
The majority of the markers we used to evaluate gliosis in our model are 
macrophage specific.  Astrocytes may also contribute to the removal of Aβ seen herein.  
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Astrocytes normally perform homeostatic functions but also react to amyloid deposits in 
the brain.  Astrocytes are capable of releasing inflammatory mediators including 
complement proteins, cytokines, prostaglandins, and reactive oxygen species (Akiyama et 
al., 2000).  These cells are spatially associated with amyloid and may be forming a glial 
scar around the deposit, though astrocyte phagocytic functions are also possible (DeWitt 
et al., 1998; Kurt et al., 1999; Mandybur et al., 1990; Wegiel et al., 2000).  One of the 
most compelling studies linking astrocytes to amyloid removal was demonstrated by 
Wyss-Coray and colleagues in 2003.  They coated brain slices from APP transgenic mice 
with adult mouse astrocytes. A significant 40 % reduction in the total amyloid burden 
was seen after 24 hour incubation.  Fucoidan and polyinosinic acid significantly blocked 
Aβ removal, implicating scavenger receptors in the process. In our studies, the only true 
astrocyte marker evaluated was GFAP.  LPS induced a significant increase in GFAP in 
all of our studies, though the reaction seemed to be transient.  In vivo, it is difficult to 
separate individual populations of cells and their activities, thus some dual labeling may 
be necessary once the receptors/mechanism of Aβ removal is discovered, in order to 
confirm whether it is microglia and/or astrocytes involved in this process. 
Assuming that the amyloid hypothesis is correct, removing Aβ should ameliorate 
the symptoms and/or progression of AD. Strategies aimed at stimulating the immune 
system to remove Aβ are at the forefront of AD research.  There is evidence from the 
human vaccine trial that treatment successfully decreased amyloid load (Schenk et al., 
2004).  An immune/inflammatory reaction was seen during the trial, which led to 
meningoencephalitis in rare cases, even though many other patients experienced 
cognitive stability and possible improvement due to the vaccine.  In transgenic mice, both 
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passive and active immunization against Aβ led to microglial activation in the process of 
lowering Aβ burden and improving cognitive performance (Wilcock et al., 2001, 2003, 
2004a,b).  Our own results with stimulation of the innate immune system with LPS 
yielded similar results: activation of microglia resulting in reductions in Aβ.  In none of 
the laboratory trials was neurodegeneration triggered by the inflammatory response. 
Taken together, one might conclude that some level of inflammation in AD is actually 
beneficial and is responsible for maintaining a balance between amyloid deposition and 
removal.   
Future studies would aim to characterize the activation state of microglia by either 
stimulating them with various agents or inhibiting specific aspects of the inflammatory 
response.  Though LPS primarily signals through TLR4, an interesting approach would 
be to activate the cells via other toll- like receptors, and then examine differential 
microglial activation while monitoring effects on amyloid burden.  In our studies, the 
inflammatory reaction seen after innate immunity stimulation was blocked by 
dexamethasone, and also prevented Aβ removal.  Targeted anti-inflammatory or anti-
oxidant treatments using compounds such as nitro-flurbiprofen, celecoxib, pioglitazone, 
or melatonin could be useful in identifying the degree of cell activation required for 
phagocytosis.  It is increasingly evident that the inflammatory response, particularly 
modulated by microglia, is very complex.  Therapeutic opportunities await analysis of the 
different stages of microglial activation, their function, morphology, and protein 
expression during both the chronic response to amyloid as well as during phagocytic 
removal of the deposits. 
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